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ABSTRACT 
The purpose of the study was to investigate the factors associated with the interruption 
of tuberculosis treatment in the Swakopmund district of Namibia. A descriptive cross-
sectional survey was conducted. Data was collected using a structured questionnaire 
administered by interviewers. The population consisted of both treatment interrupters 
and non-interrupters. The total sample was 143 respondents. The findings revealed that 
three factors were significantly associated with TB treatment interruption, namely a lack 
of formal education (p = 0.032), lack of access to media (p = 0.017), and clinic opening 
times (p = 0.000). Recommendations made include improving the support given to TB 
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CHAPTER 1 
ORIENTATION TO THE STUDY 
1.1 INTRODUCTION 
Tuberculosis (TB) is a public health priority as it is the most common cause of curable 
infectious disease worldwide. In order to avoid the emergence of drug resistance, the 
cure of sputum positive cases is essential. Adherence to treatment must therefore be 
ensured. 
 
The Swakopmund district is in the west of Namibia, a country that has one of the 
highest TB case notification rates in the world. The point estimate African regional case 
notification rate for TB is estimated at 332 per 100 000 of the population. The Namibian 
case notification rate stood at 822 per 100 000 of the population in 2004 (WHO 
2011:13; Namibia 2006a:i).  
  
The National Tuberculosis Programme (NTP) in Namibia reports that one out of every 
six TB patients interrupts TB treatment. This is a big problem for both patients and their 
communities. Drug therapy is the most important intervention for TB control, because it 
stops transmission. When patients stop their TB drugs, transmission is increased and 
drug resistance may develop (Namibia 2006a:128).  
 
The reasons for TB treatment interruption have not previously been studied in the 
Swakopmund district. Chapter 2 presents a literature study looking at what is currently 
known about the phenomenon of TB treatment interruption.  
 
1.2  BACKGROUND TO THE STUDY 
1.2.1  Introduction 
The Swakopmund district annual reports from 2005 to 2007 reveal that treatment 
success for smear positive TB cases was 80% in 2005 and 87% in 2006, while in 2007 
it dropped to 78%. At the same time the defaulter rate, which reflects treatment 
interruption, was 5% in 2005 and in 2006, but increased to 13% in 2007. Defaulter rate 
is defined as the number of patients who interrupted treatment for two consecutive 
months or more divided by total cases for the year, expressed as percentage (Namibia 
2006a:3). An increase in defaulter rate will reduce the treatment success rate, because 
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it is a negative outcome for a TB patient and will reduce the total number of patients 
who are cured or complete a TB treatment course successfully.  
 
The current situation reflected by these figures (refer to Table 1.1) needs investigating 
(Namibia 2008d:30).  
 
TABLE 1.1:  SWAKOPMUND DISTRICT TB TREATMENT SUCCESS AND 
DEFAULTER RATES 2005–2007 
YEAR TREATMENT SUCCESS DEFAULTER RATE 
2005 80% 5% 
2006 87% 5% 
2007 78% 13% 
 
In the case of smear negative TB patients in the Swakopmund district, the defaulter rate 
showed an increase from 3% in 2005 to 5% in 2006 and 6% in 2007. Smear negative 
patients are TB patients in whom TB sputum microscopy performed, usually on three 
specimens, does not identify the presence of TB bacilli (as opposed to smear positive 
TB, where TB microscopy confirms the presence of bacilli). A study in Thailand noted 
that treatment completion was lower in smear negative TB patients compared to smear 
positive (Jittimannee, Kateruttanakul, Madigan, Jittimannee, Phatkrathok, Poomichaiya 
& Panitrat 2006:338-44).  
 
At national level, the TB treatment defaulter rate for Namibia was estimated at 13%. 
This figure represented a big national problem for patients and carers (Namibia 
2006a:3). The national target for treatment success is 85%. The current treatment 
success rate for the African region is 81% (WHO 2011:39). Patient compliance is the 
key to success, and an effort must be made to solve this problem in the district under 
consideration.  
 
Drug resistance is a serious negative outcome of interruption of TB drug therapy. This 
may take the form of multi-drug resistance (MDR), which means resistance to isoniazid 
and rifampicin, two very effective TB drugs. Previous treatment was recognised as the 
strongest determinant of MDR, and a detailed study of the reasons for inadequate 
treatment was suggested as a way of improving control strategies (Faustini, Hall & 
Perucci 2006:158–63).  
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The exact number of MDR patients in Namibia is not known, as there was no MDR 
surveillance system in place at the time of the study. Taking into account the annual 
utilisation of the second-line drug, amikacin, estimates are that there may be up to 150 
MDR patients per year in Namibia (Namibia 2006a:1). The estimated prevalence of 
resistant TB in the country is 2% in new TB patients and 8% in re-treatment cases, 
according to data from the 2008 national TB resistance survey (Namibia 2009c:2). The 
number of prevalent cases of MDR TB has a direct influence on the active transmission 
of strains of MDR TB (WHO 2011:20). This problem is further compounded by the high 
HIV prevalence rate (17.8%) in Namibia (Namibia 2008c:14).  
 
1.2.2  Directly observed therapy (DOT)  
Directly observed therapy (DOT) means that a trained person observes a TB patient 
swallowing TB medicines every time as prescribed. In Namibia, DOT is regarded as the 
best method for ensuring compliance throughout the entire treatment (Namibia 
2006a:61). It is impossible to predict who will or will not comply with TB treatment. The 
use of DOT is particularly important in the intensive phase of treatment, where the 
bacillary load is highest. A high bacillary load increases the risk of transmission in the 
community.  
 
According to the World Health Organisation (WHO), DOT is the only proven way of 
achieving global treatment success targets, especially in developing countries (Namibia 
2006a:12). Community volunteers play a crucial role in supporting TB patients in the 
community. In the Swakopmund district, DOT is provided mostly by relatives or 
treatment supporters, health workers at the clinics, employers and community health 
workers. Some patients receive their treatment at their workplaces. However, despite 
the input of these volunteers, stigma can contribute to non-completion of TB treatment 
(Suri, Gan & Carpenter 2007:S505–11). It may also be that some patients stop taking 
their treatment when they feel better.  
 
Namibia has adopted the WHO treatment guidelines, which use five first-line TB drugs, 
namely rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin. These TB 
medicines are given as fixed-dose combination drug formulations packed in blister pack 
strips. First-line regimens are divided into Category I and II regimens. The initial 
(intensive) phase of treatment covers the first two months of treatment for patients on 
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Category I and three months of treatment in patients on Category II. Three to five drugs 
are given during this critical phase to ensure that the majority of TB bacilli are killed. 
After this phase, the continuation phase of treatment begins. This less critical phase 
lasts four months for Category I and five months for Category II patients. Two (in 
Category I) or three (in Category II) different TB drugs are used in the continuation 
phase, since the population of live TB bacilli is now smaller and less likely to contain 
resistant organisms. Each daily dose should ideally be administered as DOT in both the 
intensive and continuation phases, as the regimens include rifampicin (Namibia 
2006a:45–48).  
 
1.3 RESEARCH PROBLEM 
The research problem is that it is not clear which factors might affect TB treatment 
interruption in TB patients in the Swakopmund district, Erongo Region, Namibia. At the 
time of this study there was no published research on factors contributing to TB 
treatment interruption in Swakopmund district. The present study will contribute to the 
body of knowledge of this phenomenon in the Swakopmund district of Namibia. 
 
1.4 PURPOSE OF THE STUDY 
The purpose of the study is to investigate and identify factors which may have an effect 
on TB treatment interruption in TB patients in Swakopmund district, Erongo region, 
Namibia.  
 
1.5 RESEARCH METHODOLOGY 
The research methodology will be discussed in detail in Chapter 3.  
 
1.5.1  Research strategy 
This descriptive cross-sectional study is done by means of a survey.  
 
1.5.2  Research setting 
The study was done at the TB clinics in the towns of Swakopmund, Arandis and Henties 
Bay in the Swakopmund district, from January 2007 to December 2008.  
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The population was made up of patients who started TB treatment in the Swakopmund 
district from January 2007 to December 2008. All were above 15 years of age; very ill 
patients and drug resistant cases were excluded from the study.  
1.5.3  Sampling 
The sampling method used in this study is a non-probability form of sampling, namely 
purposive sampling.  
 
1.6  RATIONALE OF THE STUDY 
This study is essential because TB treatment interruption is known to be related to 
adverse outcomes. The importance of treatment interruptions, and their effect on 
outcomes of TB treatment, was shown in a retrospective study in Russia (Jakubowiak, 
Bogorodskaya, Borisov, Danilova & Kourbatova 2009:362–8). That study noted that 
treatment interruptions were frequent. In the intensive phase, 63% of the eventual 
defaulters interrupted treatment, compared to 36% of the patients in the eventual 
treatment success group. In the continuation phase, 30% of the eventual defaulters and 
45% of the eventual treatment success patients interrupted treatment. The period of 
treatment interruption ranged from 1 to 127 days. The probability of default was greater 
than or equal to 50% in patients who missed two to three consecutive days of treatment 
in the intensive phase or at least one day in the continuation phase.  
 
An understanding of treatment interruption and its determinants in settings with a high 
HIV prevalence is essential to assist in designing effective interventions to limit the 
development and spread of drug-resistant TB, including extensively drug-resistant 
(XDR) TB, as defined by the Centers for Disease Control (CDC 2006:2792). High 
quality directly observed treatment, short-course (DOTS) is affordable and effective, 
especially in resource-poor settings (USAID 2011).  
 
1.7  DEFINITION OF TERMS 
1.7.1  Treatment interruption 
For the purpose of this study, treatment interruption will be defined as missing a 
cumulative total of seven or more days of TB treatment. This term will be used 
interchangeably with the phrase “did not complete treatment”.  
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1.7.2  Defaulter rate  
For the purposes of this study, the defaulter rate will be regarded as the number of TB 
patients missing two months or more of TB treatment after completing at least four 
weeks of TB treatment, divided by the total number of TB patients for a given period 
(refer to paragraph 1.2.1).  
 
1.7.3  Directly observed therapy (DOT)  
DOT means that a trained person observes a TB patient taking and swallowing their TB 
medicines each time. This is a WHO concept (Namibia 2006a:11).  
 
1.7.4  Category I treatment 
Category I treatment consists of a two-month initial phase of rifampicin, isoniazid, 
pyrazinamide and ethambutol daily followed by four-month continuation phase of 
rifampicin and isoniazid daily. This six-month regimen has been favoured by the WHO 
for all settings since 2004 (Wells, Konduri, Chen, Lee, Ignatius, Gardiner & Schwalbe 
2010:1538–47).  
 
1.7.5  Category II treatment 
Category II treatment has a three-month initial phase which is subdivided into two 
months of rifampicin, isoniazid, pyrazinamide and ethambutol daily and streptomycin on 
weekdays followed by one month of rifampicin, isoniazid, pyrazinamide and ethambutol 
daily. The continuation phase consists of five months of rifampicin, isoniazid and 
ethambutol daily.  
 
1.8  ORGANISATION OF THE STUDY AND CONCLUSION 
This chapter briefly introduced the present study, which is laid out as follows:  
 
 Chapter 1 presents the orientation to the study.  
 Chapter 2 covers the literature review.  
 Chapter 3 describes the research design and methodology.  
 Chapter 4 is the analysis, presentation and description of the research findings.  
 Chapter 5 draws together the conclusions and recommendations.  
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The study seeks to contribute to an understanding of TB treatment interruption and its 
determinants to assist in the design of effective interventions which will improve 




2.1  INTRODUCTION 
Data obtained from the district annual reports in Swakopmund from 2005 to 2007 reveal 
an increasing defaulter rate in the use of TB medicines in the district (Table 1.1). 
The national target for treatment success is 85%. Since patient compliance is the key to 
success, it is important that this problem be solved in the Swakopmund district 
(Williams, Alarcon, Jittimanee, Walusimbi, Sebek, Berga & Villa 2008; Namibia 
2006a:59).  
 
2.2  DIRECTLY OBSERVED TREATMENT SHORT-COURSE (DOTS) AND 
SELF-ADMINISTRATION  
There is an inherent problem of regularity in drug intake with respect to long-term 
treatments such as TB. Since the period of self-administered treatment is very long,  
it is viewed as a problem which may lead to treatment interruption. For patients on self-
administration, interruption of treatment is more likely in developing countries (Lewin, 
Dick, Zwarenstein & Lombard 2005:250–9).  
 
In 1993, the WHO introduced the DOTS strategy, which consists of five components, 
namely: 
 
 political commitment by governments  
 improved laboratory services 
 a continuous supply of good quality drugs  
 a reporting system to document the success or failure of the treatment of the 
individual patient and the TB programme itself  
 effective case management through direct observation of treatment by an 
independent and trained third party (Frieden & Sbarbaro 2007:30–33).  
 
As was indicated in the first chapter, in Namibia DOT is regarded as the best method for 
ensuring compliance throughout the entire treatment. The use of DOT is particularly 
important in the intensive phase, when the bacillary load is at its highest. A high 
bacillary load increases the risk of transmission in the community.  
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Community volunteers play a crucial role in supporting TB patients on treatment in the 
community. For example, they act as TB lifestyle ambassadors who encourage patients 
to complete their treatment. However, despite the DOTS strategy, stigma remains a 
factor that can contribute to non-completion of TB treatment (Namibia 2006a:61; Suri et 
al 2007:S505–11) (See paragraph 2.3.9).  
 
Many other factors can contribute to treatment interruption in the context of a DOT 
programme. A study in Hong Kong by Chang, Leung and Tam (2004:1492–8) found that 
current smoking, past TB treatment with default, and poor adherence at the beginning of 
treatment were strongly associated with treatment interruption. Hospitalisation, on the 
other hand, was found to be protective.  
 
A systematic review comparing DOT and self-administered treatment (SAT) found no 
statistically significant difference between DOT and SAT. DOT was found to have no 
quantitatively important effect on either treatment completion or cure in patients 
receiving TB treatment (Volmink & Garner 2007:CD003343). According to this 
systematic review, DOT and SAT lead to similar treatment outcomes. This finding is 
contradicted by a 2007 national TB prevalence survey in the Philippines showing 
a significant decline in bacteriologically confirmed TB in 10 the years following the 
launch of DOT in 1996 in that country. This decline in TB burden occurred despite an 
increase in the overall magnitude of poverty in the Philippines, and is attributed to 
treatment of infectious TB patients through DOTS (Tupasi, Radhakrishna, Chua, 
Mangubat, Guilatco, Galipot, Ramos, Quelapio, Beltran, Legaspi, Vianzon & Lagahid 
2009:1224–1230).  
 
A study on DOT identified five major themes that lead to treatment interruption (Noyes 
and Popay 2007:227–43). These are:  
 
 socio-economic circumstances  
 material resources and individual agency 
 explanatory models and knowledge systems about TB treatment 
 experience of stigma and public discourse on TB 
 sanctions, incentives and support, and social relationships of care. 
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2.3  FACTORS CONTRIBUTING TO TREATMENT INTERRUPTION 
The factors that cause treatment interruption are complex and dynamic (Munro, Lewin, 
Smith, Engel, Fretheim & Volmink 2007a:238; Sagbakken, Frich & Bjune 2008). These 
factors will be elaborated on in this section.  
 
2.3.1  Health promotion theories as explanation of adherence behaviour 
A number of theories have been put forward to try to explain the adherence behaviour 
of patients in general; these can also be applied to TB patients. Health promotion 
theories that apply to individual behaviour are: the health belief model, the theory of 
reasoned action, social cognitive theory, and transtheoretical (stages of change) theory. 
These theories explain health behaviour at the individual level. It is important to note, 
however, that a study in South Africa in 2007 reviewed the usefulness of health 
behaviour theories in developing interventions to promote adherence to TB and HIV 
medications but found little evidence in support of these theories (Munro, Lewin, Swart 
& Volmink 2007b:104). Further studies and models to find ways of improving adherence 
to long-term treatments were suggested by other authors, but the effects of these still 
need to be evaluated (Nutbeam and Harris 2004:10–23).  
 
A review of 38 systematic reviews on the effectiveness of adherence interventions has 
also been done. This review of reviews found some adherence interventions to have a 
theoretical explanation, such as incentives and reminders, but some effective 
interventions had no theoretical explanation at all. Van Dulmen, Sluijs, Van Dijk, De 
Ridder, Heerdink and Bensing (2007:55) identified a need for further study in this area.  
 
2.3.2  Support for TB patients on treatment 
The responsibility for TB treatment and completion should not be left to the TB patient 
alone. Patients must not carry the sole responsibility for adherence; this has to be a 
team effort. In interaction with patients in Namibia, the researcher noted a lack of 
psychological support from close relatives and the community at large. DOT is not 
optimal without moral support, bonding and mutual respect (Namibia 2006a:61).  
 
A quantitative study done in India associated treatment interruption with poor 
interpersonal communication and lack of attention and support. Health care workers’ 
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mistakes and behaviour can lead to discontinuation of treatment (Jaiswal, Singh, 
Ogden, Porter, Sharma, Sarin, Arora & Jain 2003:625–33). Another study graded the 
communication ability of TB medication dispensers as good, fair or poor. Respondents 
rated the way the dispenser communicated use of medication, associated side effects, 
benefits and risks of non-adherence as well as the respect shown by the dispenser for 
the patient’s autonomy and integrity. It was found that poor or fair grades for 
communication were associated with non-adherence (Mishra, Hansen, Sabroe & Kafle 
2006:29–37).  
 
2.3.3  Access 
Access to treatment is an important factor determining treatment interruption. Lack of 
transportation and large distances from the health centres are associated with non-
adherence. Movement to another area and losing contact with the treatment centre is 
also a factor (WHO 2003).  
 
Some of the reasons given for ineffective DOT implementation are rigidity of clinic time 
tables, lack of staff motivation, and poor relations between staff and patients (Namibia 
2006a:1; Lewin et al 2005:250–9).  
 
2.3.4  Side effects of TB medication 
Authors studied noted that unwanted side effects were an important factor contributing 
to treatment interruption (Jaiswal et al 2003:625–33). Studies comparing fixed drug 
combinations with free drug components are limited. The term ‘free drug components’ 
refers to single dose formulations, which include rifampicin, isoniazid, pyrazinamide and 
ethambutol. A systematic review finds that fixed drug combinations result in a 26% 
reduction in non-compliance (Bangalore, Kamalakkannan, Parkar and Messerli 
2007:713–19). It is important to note, however, that of the nine studies that met the 
criteria for inclusion in this review, only two related to TB patients.  
 
The NTP currently uses fixed drug combinations. These are combinations of four drugs 
(rifampicin, isoniazid, pyrazinamide, ethambutol), three drugs (rifampicin, isoniazid, 
ethambutol) or two drugs (rifampicin and isoniazid) which are given according to weight 
categories, diagnostic classification and treatment regimen (Namibia 2006a:48). Fixed 
drug combinations have the advantage of preventing monotherapy (reducing the 
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likelihood of TB drug resistance) and also simplify regimens for patients and doctors, 
procurement and distribution systems. They may increase adherence, but supporting 
evidence for this scarce (Wells et al 2010:1538–47). 
 
2.3.5  Co-morbidity 
A retrospective study shows that all causes of interruption of anti-TB medication occur 
with similar frequency in HIV positive and HIV negative individuals. This is despite the 
greater rate of side effects to TB medicines found in HIV positive individuals compared 
to HIV negative TB patients (Breen, Miller, Gorsuch, Smith, Schwenk, Holmes, 
Ballinger, Swaden, Johnson, Cropley & Lipman 2006:791–4). The rate of co-morbidity 
for TB and HIV is 59% in Namibia (Namibia 2009a:14).  
 
2.3.6  Knowledge, beliefs, perceptions and unknown factors 
A lack of knowledge of the disease (TB) and its treatment can contribute to interruption. 
Conversely, the knowledge that TB is curable can be an important factor in encouraging 
compliance. However, a qualitative study in Limpopo province of South Africa found that 
knowledge, socio-demographic factors, health-seeking behaviour and health beliefs 
were not significant factors in TB treatment interruption (Peltzer 2002:55–67).  
 
TB patients may start to feel better and stop taking their medication when they feel that 
they are cured. Treatment seems to become less important and more inconvenient 
when one is feeling better. Taking treatment erratically (as opposed to absconding from 
the treatment programme) is noted as a problem. Erratic medication is associated with 
the development of drug resistance, whereas stopping all medication is less likely to 
lead to selection of resistant TB organisms (Namibia 2006a:69–72).  
 
Sometimes a TB patient will not provide the reasons for interruption, opting rather to 
keep this information to themselves. These are non-spoken issues that influence the 
phenomenon of treatment interruption (WHO 2003).  
 
Western medicine and traditional medicine coexist in most of Africa. In a personal 
communication with the researcher, a patient revealed that a traditional healer had 
asked him to stop his TB medication. This indicates that cultural perceptions of disease 
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are very important (personal interview with non-identifiable person, August 2008). It is 
possible that culture may play a more significant role than is realised.  
 
2.3.7  Family, work and migration issues 
Family commitments may be another factor leading patients to interrupt treatment. In 
the perception of the researcher, the inconvenience of having small children at home 
and having to bring them along to the health centre or clinic may cause some patients to 
tire of the treatment programme.  
 
Work problems and work commitments may also cause some TB patients to interrupt, 
for example when employers do not understand the importance of the treatment 
(Jaiswal et al 2003:625–33; WHO 2003). A study in Malawi reported TB patients being 
dismissed from work due to illness and being denied continuation of employment after 
completion of treatment (Somma, Thomas, Karim, Kemp, Arias, Auer, Gosoniu, 
Abouihia & Weiss 2008:856–66).  
 
2.3.8  Socio-economic factors  
A retrospective study in Russia identifies alcohol abuse, homelessness and lack of 
social support as socio-economic factors that lead to non-adherence (Jakubowiak, 
Bogorodskaya, Borisov, Danilova and Kourbatova 2007:46–53). Alcoholism, especially, 
is recognised as a complicating factor when it come to non-adherence (Jaiswal et al 
2003:625–33).  
 
In Nepal, unemployment, low-status occupation, low annual income and a high cost of 
travelling are associated with interruption. However, living conditions, literacy levels and 
difficulty financing treatment are found not to be associated with treatment interruption 
(Mishra, Hansen, Sabroe & Kafle 2005:1134–9).  
 
A qualitative phenomenological study using purposive sampling at a primary clinic in 
South Africa found poverty to be associated with non-adherence, while economic 
resources were associated with adherence (Naidoo, Dick & Cooper 2009:55–70). This 
is important because patients with TB and HIV co-infection are considered for disability 
grants in Namibia via the Social Services department when their disease is advanced. 
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2.3.9  Factors related to programmes and incentives 
The (South African) Public Health Act No 36 of 1919, which was made applicable to 
what was then South West Africa, is outdated and is currently undergoing revision to 
make it more relevant to issues such as treatment interruption. 
 
The researcher observed that TB facilities (TB clinics) are not well integrated either with 
the community of Swakopmund district or with general health services. There were no 
community-based health workers working within the district. Existing TB DOT promoters 
operated only at the TB clinic. This implied, in fact, that these DOT promoters were not 
fulfilling their role as envisaged by the WHO.  
 
Doctors and nurses do not rotate through the TB clinic. Introducing TB lifestyle to 
ambassadors carry TB messages into the community may improve the link with the 
community.  
 
The current district TB programme needs to be integrated into general district health 
services. The activities and information generated in the programme should be 
coordinated and shared with the rest of the district team (Namibia 2008b:47–9).  
 
2.3.10  Stigma as a factor  
Stigma affects the quality of a patient’s life and the effectiveness of TB control. TB is a 
stigmatised disease. Some patients simply do not want it to be known that they are 
receiving TB treatment (WHO 2003).  
 
Patients with TB suffer from social isolation as a result of unscientific beliefs about TB 
and its transmission. The prejudice associated with TB may be due to fear of infection 
and an aversion to the poverty associated with TB (Jaramillo 1999:71).  
 
A multinational study in Bangladesh, India, Malawi and Colombia shows an association 
between HIV/AIDS and TB-related stigma. It notes an increased delay in health-seeking 
along with non-disclosure of status. TB-HIV infected patients are less likely to believe 
positive messages about TB cure in areas where there is no access to anti-retroviral 
treatment. The TB stigma is also linked to concerns about reduced marital prospects for 
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women in India and Malawi. This stigma may lead to a patient dropping out of treatment 
(Somma et al 2008:856–66).  
 
2.4  CONCLUSION 
This chapter gave an overview of DOT and factors contributing to treatment interruption. 
In the opinion of the researcher, DOT will require strong leadership from the Namibian 
NTP and a significant commitment of resources, especially human resources. The NTP 
should bear more responsibility than the individual patient. DOT might work if resources 
are universally employed, persistently and with good leadership. The DOT strategy 
needs resources, especially in countries where the TB caseload is high. DOT will not 
work in a rigid, inflexible environment. Issues such as distance to be travelled can be a 
deterrent (Frieden & Sbarbaro 2007:30-33). However, there is a counter-argument that 
DOT is only beneficial due to other interventions being implemented simultaneously, 
rather than DOT itself being an adherence-promoting strategy. Quite clearly, there is a 






METHODOLOGY AND RESEARCH DESIGN 
3.1  INTRODUCTION 
The purpose of the study was to investigate and identify factors that may have an effect 
on TB treatment interruption in TB patients in the Swakopmund district, Erongo Region, 
Namibia.  
 
3.2  RESEARCH DESIGN 
Epidemiological studies seek to identify the determinants of health as well as the 
determinants of disease. According to Bailey, Vardulaki, Langham and Chandramohan, 
“[t]he determinants of health states or events are definable factors that influence the 
occurrence of health related events” (2005:1).  
 
The research for this descriptive cross-sectional study was done by means of a survey.  
 
3.2.1  Survey 
Survey research is a research technique in which a researcher selects a sample of 
respondents from a large population and administers a standardised questionnaire to 
each respondent. The individual respondent is usually the unit of analysis. Surveys can 
be used for descriptive, explanatory and exploratory purposes (Babbie and Mouton 
2004:230–32).  
 
3.2.1.1  Descriptive cross-sectional survey  
A descriptive cross-sectional survey, as was done in this study, gathers data at a 
particular point in time, and the data collected provides the description of the study 
population. The relationship between variables at a point in time can be determined 
(Brink, Van der Walt & Van Rensburg 2006:105).  
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3.2.2  Advantages of surveys  
Surveys have the following advantages: 
 
 Survey research is less expensive than most other forms of research.  
 It saves time and effort.  
 Survey research enables a researcher to obtain information from a population that 
is too large to be observed directly.  
 Surveys are useful for describing the characteristics of a large population, 
including attitude and orientation.  
 The survey method can use standardised or newly designed questionnaires.  
 Usually the survey method is also very reliable, provided all subjects are exposed 
to the same carefully worded questionnaire (Babbie & Mouton 2004:262–5).  
 
3.2.3  Disadvantages of surveys 
Surveys have the following disadvantages: 
 
 The requirement for standardisation can result in missing some of the unique 
characteristics of each respondent.  
 Some surveys fail to consider the total social life context of an individual.  
 They can be inflexible in that the initial study design does not change despite 
changing field conditions.  
 Surveys are also subject to artificiality because the answers a person gives do not 
necessarily reflect the person’s true views. This means that surveys cannot 
measure social action as they get self-reported data on past or future action.  
 Some attitudes under study can be affected by the study itself.  
 Survey research, while strong on reliability, is weak on validity (Babbie & Mouton 
2004:262–5).  
 
3.3  STUDY POPULATION AND SAMPLING 
3.3.1  Population 
A population is the theoretically specified aggregation of study units or elements 
(Babbie & Mouton 2004:173). The theoretical population of the present study 
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constituted all TB patients in the Swakopmund district. A sample size of 143 patients 
was used. 
The study population was all TB patients who started treatment in Swakopmund District, 
which includes the towns of Henties Bay and Arandis, between January 2007 and 
December 2008. It is from this study population that the sample was selected.  
 
Swakopmund district is in the Erongo region of Namibia. The district has three clinics, 
namely Tamariskia, Henties Bay and Arandis. The total population of Swakopmund is 
about 43 000. A third of the population is under 5 years of age. The literacy rate is 86%, 
while the unemployment rate stands at 30% (Namibia 2003).  
 
3.3.2  Sampling 
A non-probability sampling method, namely purposive sampling, was used. Purposive 
sampling is sampling which is done on the basis of knowledge of the population and its 
elements. It is based on one’s judgement and the purpose of the study (Babbie & 
Mouton 2004:166–7). The use of purposive sampling enabled the researcher to select 
cases that met the criteria of interest for treatment interruption. It was also possible to 
select those TB patients who had been on treatment for more than four weeks at all 
three TB clinics in the district. This method of sampling saved time, money and effort.  
 
However, because purposive sampling is a non-probability sampling method, it is 
possible that the sample may not be representative.  
 
3.3.2.1  Inclusion criteria  
In order to be included in this study, TB patients in the Swakopmund district had to: 
  
 be over the age of 15 years 
 have been entered in the TB treatment register during 2007 or 2008 
 have completed more than four weeks on TB treatment  
 either have not interrupted their treatment at all, or have interrupted their TB 
treatment for a cumulative seven days or more (for all types of TB). 
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3.3.2.2 Exclusion criteria 
The following were excluded from the study (despite meeting the above criteria): 
 
 patients whose TB treatment was not started in the Swakopmund district  
 TB patients who were too sick to be interviewed 
 MDR and XDR patients.  
 
3.3.2.3  Ethical issues related to sampling 
Because the sampling method was purposive, great caution is required. Data obtained 
from this study cannot be generalised.  
 
3.4  DATA COLLECTION 
3.4.1  Data-collection approach and method 
Data was collected by means of a questionnaire administered by field workers (TB 
DOTS promoters) in a structured interview with each respondent. Each patient was 
matched to one interviewer; an interviewer could be allocated several patients. 
 
3.4.2  Development and testing of the data-collecting instrument 
No existing questionnaire could be found that could be used for this study and this study 
context.  
 
The literature review was used to construct questions based on factors associated with 
TB treatment interruption that were identified in the literature. Elements of the health 
belief model, theory of reasoned action, social cognitive theory and transtheoretical 
stages of change theory were also used.  
 
These elements included knowledge about TB treatment interruption, some of its 
serious consequences, perceived susceptibility to those serious consequences and 
level of support in the patient’s environment. Stages of change from pre-contemplation, 
contemplation, action, maintenance and relapse or termination of behaviour elements 
were also applied in developing the questionnaire (Nutbeam & Harris 2005:10–23).  
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The questionnaire was developed in English, which is the official language of Namibia. 
Interviewers could speak the local languages and translated aspects of the 
questionnaire to the home language of a respondent where it was found necessary to 
do so.  
 
3.4.2.1  Pre-testing the instrument 
A pilot study is a small-scale study conducted prior to the main study on a limited 
number of subjects from the population. The purpose of the pilot study is to investigate 
the feasibility of the proposed study and to detect possible flaws in the data-collecting 
instrument (Brink et al 2006:166). No official pilot study was done in this research. 
However, the instrument was pre-tested.  
 
The research instrument was pre-tested before the main study commenced. This 
helped to estimate the time it would take to interview each respondent. Issues like 
clarity, ease, ambiguities and difficult wording were solved. The pre-testing of the 
questionnaire was particularly useful in view of the multiple languages and cultures in 
the study population.  
 
The pre-testing of the instrument took place in the TB ward at Swakopmund hospital. 
Six TB patients were involved. The respondents in the pre-testing phase were not 
included in the main study.  
 
3.4.3  Characteristics of the data-collecting instrument  
The questionnaire contained closed- and open-ended questions. Closed-ended 
questions were in a multiple-choice format, where the respondent was asked to select 
answers from a list of options. This facilitated greater uniformity and easier processing 
of answers by computer. An effort was made to make the questions exhaustive and 
mutually exclusive. During the development of the data-collecting tool, measures were 
taken to avoid double-barrelled questions and to ensure that everything was clear. The 
ability of respondents to the answer questions was determined through the pre-testing 
of the data-collecting tool. Answers to some of the questions (for example the patient’s 
HIV status) were obtained from the patient records rather than by interview. The 
questionnaire is attached as Annexure D.  
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3.4.3.1 Questionnaire  
The questionnaire comprises nine sections. Section A contains the biographical data. 
Section B is about the support that the TB patient received from other persons. Section 
C is about the reasons for and perceived consequences of stopping TB medication. 
Section D is on DOT. Section E investigates the effects and side effects of medication. 
Section F focuses on access to TB medication. Section G gathers information about the 
patient–provider relationship, and Section H is on stigma attached to the disease. 
Lastly, Section I is on substance use.  
 
Table 3.1 briefly describes the contents of each section of the questionnaire and gives 
the motivation for including each one.  
 
A written consent form accompanied the questionnaire and is attached as Annexure C. 
The consent form informed the respondent about the research and the principles of 
voluntary participation and informed consent. This had to be included for ethical 
reasons.  
 
3.4.4  The data-collection process  
TB patients were selected from TB facility registers at the TB clinics by identifying those 
who met the inclusion criteria. Subsequently the data-collecting instrument (the 
questionnaire) was administered to obtain data from the selected TB patients. Direct 
individual interviews were conducted to ensure clear answers. The trained interviewers 
asked questions orally and recorded the answers on the questionnaires. This method 
was particularly useful since not all the respondents were able to read or write.  
 
The interviewers were TB DOT promoters from the same community as the 
respondents. An attempt was made to match interviewers and respondents with respect 
to language, gender and age, but this was not always possible, due to the diversity of 
culture and language in Swakopmund district. Interviewers were encouraged to dress 
appropriately, be thoroughly familiar with the questionnaire and to be neutral at all 
times. They were instructed to record answers in the respondents’ exact words. 
Interviewers were given a day of training and received 10 Namibian dollars per 
respondent interviewed as an incentive.  
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TABLE 3.1:  QUESTIONNAIRE SECTIONS, DESCRIPTION AND MOTIVATION OF 
QUESTIONS 
SECTIONS QUESTIONS – DESCRIPTION AND MOTIVATION 
Section A: 
Biographical data 
Respondents were asked to give biographical data.  
The purpose was to be able to provide a profile of the sample. The data also 
enabled investigation of the relationship between the biographical data and 
possible factors associated with treatment interruption.  
Section B:  
Support that TB 
patients received 
from other persons  
Respondents were asked whether they had completed taking all doses of 
TB medicines prior to the interview date and to describe the nature of 
support they had received from health care workers, community and media.  
 
This is important since TB treatment interruption can potentially be 
associated with lack of support. This question also helped the researcher to 
identify TB treatment interrupters.  
Section C: 
Reasons for and 
perceived 
consequences  
of stopping TB 
medicines  
Respondents were requested to give reasons why they had interrupted their 
TB treatment, as well as the perceived consequences of such behaviour.  
 
This information is important because it gives insight into the reasons for 
treatment interruption, and essentially this is the purpose of the study. 
Consequences of behaviour can influence individual behaviour, as 
explained by the health belief model (Nutbeam & Harris 2004:10–14).  
Section D:  
Directly observed 
therapy 
Respondents were requested to explain how they took their TB medicines.  
 
This question was important to determine the exact way DOT is practised, or 




Respondents were requested to reveal whether they experienced side 
effects and what action they were taking.  
 
This was included because side effects have the potential to influence 
treatment adherence.  
Section F:  
Access to TB 
medication 
Respondents were asked about physical and financial access to TB 
treatment. Any change of physical address was also noted.  
 
This was crucial in determining whether reduced access to TB treatment 
was a potential reason for treatment interruption by patients in the district.  
Section G:  
Patient–provider 
relationship 
Patients were requested to describe their experience when visiting health 
facilities for TB treatment.  
 
This is important because patients’ experiences and the quality of care 
might influence TB treatment adherence.  
Section H:  
Stigma 
Respondents were asked questions regarding the reactions of their relatives 
and friends to their having TB, and if they perceived stigma as a problem.  
 
Because stigma can influence adherence, it had to be determined whether 
stigma still contributed to TB treatment interruption by patients in the district.  
Section I: 
Substance use 
Respondents were asked about alcohol and cigarette consumption.  
 
This was necessary in order to find out whether substance use contributed 
to treatment interruption.  
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At the end of the data-collecting process, the interviewers were debriefed on the whole 
process.  
 
3.4.5  Ethical considerations related to data collection 
Permission for the study was obtained from the Swakopmund District Coordinating 
Committee, the Erongo Regional Management Team, the Chief Medical Officer of 
Erongo Region, the Regional Director of Erongo Region and the Permanent Secretary 
of the Ministry of Health in Namibia. A copy of this permission is attached as 
Annexure B.  
 
Ethical clearance was also obtained from Unisa’s Department of Health Studies 
Research and Ethics Committee. The Clearance Certificate is attached as Annexure A. 
 
Each TB patient had the choice to participate or not to participate in the study. 
Participation was voluntary, and they could decide independently. Participants under the 
age of 18 years obtained additional written consent from their parents or guardians. A 
participant could withdraw at any point in the study. No one was victimised for not being 
willing to participate in the study. Non-participants still received all the necessary care 
and treatment they needed from the health services.  
 
The study was explained to the patients in their own languages, and they were free to 
ask questions if there were issues they did not understand. Verbal and written informed 
consent was obtained from all respondents.  
 
Confidentiality was ensured as no identifying details were written on the questionnaires 
to link anyone to the data obtained. The interviews were conducted in private and 
participants remained anonymous – the completed questionnaires did not give any 
names. 
 
The study avoided harm to participants. This included emotional, physical, social and 
financial harm. The interviewers were trained to maintain a non-judgemental attitude 
towards patients.  
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To an extent, participation in the study did disrupt normal activities for the respondents. 
The study asked people to reveal deviant behaviour and personal issues which they 
might have been ashamed of. It is possible that participants experienced psychological 
discomfort, and this could be seen as a possible limitation.  
 
The inclusion criteria listed earlier were applied throughout the study.  
 
3.4.6  Data analysis 
The completed questionnaires were analysed using the SPSS 15.0 statistical package 
and Microsoft Excel. Multiple-choice questions were coded and entered into the SPSS 
database. Numerical variable responses were analysed using summary descriptive 
statistics (measures of centrality and dispersion). Non-numeric responses were 
analysed and categories were identified. Frequency distributions and charts were 
constructed to display patterns of treatment interruption. Relationships between 
research variables and demographic factors were analysed for some of the data using 
cross-tabulations and chi-square (χ
2
) tests for independence. The open-ended 
questions were analysed to identify themes in a qualitative way; however, questions of 
this type were limited in number.  
 
3.5 VALIDITY AND RELIABILITY OF THE STUDY 
3.5.1  Validity 
Validity as a broad concept refers to the truthfulness or accuracy of research findings 
(Saks & Allsop 2008:416).  
 
Internal validity refers to the approximate truth of the conclusions regarding a cause–
effect relationship. In this respect, internal validity is relevant only to studies that seek to 
establish causal relationships (Babbie & Mouton 2004:217–19).  
 
External validity relates to the generalisability of the study findings (Babbie & Mouton 
2004:219). It refers to the approximate truth of conclusions. The main threat to external 
validity in this study is the non-random sampling method, namely purposive sampling, 
that was used to select respondents. This does not guarantee a representative sample.  
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Since the study was done under national programme conditions in Swakopmund and no 
intervention was given to participants, the findings could be generalised to a district 
similar to Swakopmund in the country. The data was collected from the records and 
patients retrospectively, thus also reducing social desirability.  
 
The place and timing of the study could limit generalisability. New interventions, such as 
communication for behavioural change (COMBI), have been introduced in the NTP 
since the study was conducted. Such interventions may change (or may already have 
changed) the behaviour of TB patients in the country.  
 
Content validity is the outcome measure or finding that includes all issues considered 
essential by participants and experts in the field (Saks and Allsop 2008:416). Content 
validity was ensured because the questionnaire measured the factors under study, 
namely the reasons for TB treatment interruption. The questionnaire was based on an 
extensive literature review of studies in Namibia and the rest of the world, and also 
incorporated questions used in previous studies on TB. It was given to the staff in the 
TB department at district, regional and national level for comment.  
 
As mentioned earlier, the questionnaire was pre-tested on six TB patients in the TB 
ward at the Swakopmund hospital.  
 
3.5.2  Reliability 
Reliability refers to the degree to which a data-collecting instrument can be depended 
on to give consistent results if used repeatedly over time on the same person or by 
different researchers. Reliability and validity are closely related, and both qualities 
should be considered in the selection of a research instrument (Brink et al 2006:163–5).  
 
Reliability was achieved by using short, accurate phrases and avoiding leading 
questions. Questions asked were relevant to the issue being researched. Negative 
questions were avoided. Respondents were informed about the purpose of the interview 
and encouraged to answer truthfully. Because some questions could have induced 
embarrassment or feelings of irresponsibility, the interviewers were trained to avoid 
allowing their attitudes and behaviour to influence the answers. In some cases, 
respondents may have wanted to give socially desirable answers. To minimise this 
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effect, TB records were used to confirm aspects such as treatment interruption. 
Interviewers assisted respondents to understand the questionnaire by translating 
questions where necessary.  
 
The retrospective nature of some of the questions could have resulted in recall bias. 
Selective memory, along with the desire to give socially desirable answers, may 
contribute to bias in the study.  
 
Selection bias would have occurred since study participants were obtained using 
available records at the TB clinics, selected by purposive sampling. This affects the 
representativeness of the study. Since this was not a case control study, it was not 
necessary to select subjects according to exposure and outcome.  
 
The way in which patients were requested to participate in the study was the same for 
all. Patients were approached at the TB clinic and requested to participate. During this 
interaction, potential participants were given detailed information about the study. 
Verbal and written consent was obtained before each interview was conducted. The 
interviews were conducted in private rooms with individual respondents to reduce the 
tendency to give socially desirable answers. Patients were interviewed Monday to 
Sunday between 8 am and 5 pm. The researcher obtained official time off from work to 
conduct this study.  
 
The services of an official bio-statistician were enlisted to enhance the reliability of the 
study.  
 
3.6 CONCLUSION  
Chapter 3 described the research design and methodology of the study. The research 
design took the form of a descriptive cross-sectional survey. In total, 143 TB patients 
were interviewed using questionnaires administered by trained interviewers in face-to-







ANALYSIS, PRESENTATION AND DESCRIPTION  
OF RESEARCH FINDINGS 
4.1 INTRODUCTION 
TB records were reviewed at three clinics, namely the Tamariskia clinic, Henties Bay 
clinic and Arandis clinic, in the period from January 2007 to December 2008 in order to 
identify possible participants for this study. A sample of 143 participants was obtained, 
and the data-collecting instrument was used by interviewers on a one-on-one basis in 
order to collect data.  
 
The study excluded TB patients who had been on treatment for less than a month, 
children under 15 years of age, very ill patients, patients who were transferred and drug-
resistant patients.  
 
4.2 DATA MANAGEMENT AND ANALYSIS 
The SPSS 15.0 statistical package and Microsoft Excel were used to analyse the 
completed questionnaires. A statistician assisted in the final interpretation of results.  
 
Numerical variable responses were analysed using descriptive statistics. Inferential 
statistical methods were used to analyse the relationships between some of the 
research variables. The chi-square test was used because it allows two categorical-type 
datasets to be compared to determine if there is a relationship between them (Maltby, 
Day & Williams 2007:257). Tables were used to display the data. Reporting on the chi-
square test is covered in Chapter 5.  
 
All open-ended questions were analysed manually and individually, using aspects of 
qualitative methodology where necessary. Non-numeric responses were analysed in a 
qualitative manner and categories identified.  
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4.3  RESEARCH RESULTS 
The research findings will be related to findings reflected in the literature review where 
possible. Correlations and contrasts in response to different questions will be indicated. 
Unexpected findings are also presented, and explanations suggested where possible.  
 
In the data discussion sections below, each question is identified by the section number 
(letter) as well as the question number. For example, the second question in Section B 
(Support) is numbered B2- followed by the letter used in the questionnaire, if applicable, 
in lower case: B2a or B2b.  
 
4.3.1  Demographic data (Section A)  
4.3.1.1 Age (Question A1)  
Although the sample size is 143, only 137 (95.8%) questionnaires recorded age, and 
the descriptive statistics were calculated from these cases. The patient record files did 
not give the ages of the other six respondents.  
 
TABLE 4.1: AGES OF PATIENTS IN TUBERCULOSIS RESEARCH GROUP  
 
The average age of the participants was 35.7 years (minimum age was 15 years and 
the maximum age was 76 years) with a standard deviation, σ, of 11.1 years. National 
data indicates that the peak age group for new smear positive TB was 25 to 34 years 
(Namibia 2009a:4).  
 
4.3.1.2 Gender (Question A2)  
The question about gender was completed by all respondents.  
 
TABLE 4.2: GENDER OF RESEARCH GROUP MEMBERS 
GENDER NUMBER (N)  PERCENTAGE (%)  
Male  97   65.0  
Female  50   45.0 
Total  143  100.0 
  N RANGE MINIMUM MAXIMUM MEAN STD DEVIATION 
Age data 137 61 15 76 35.7 11.1 
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The majority of the respondents in this survey were male (97, or 65%). National data for 
Namibia shows that 58% of all new smear positive PTB cases reported in 2008 were 
male; 42% were female. The predominance of males over females was noted to need 
further investigation in order to guide future interventions (Namibia 2009a:4).  
 
4.3.1.3  Patient’s Address (Question A3)   
The patients in the research group came from a variety of places in and around the 
towns of Swakopmund, Henties Bay and Arandis, which are all traditionally served by 
the three TB clinics.  
 
When commencing TB treatment, respondents were staying in various places such as 
Build Together, Mondesa, Henties Bay and Tamariskia served by the three clinics.  
 
The last question in section F on access of treatment was included to determine if 
patients moved during their treatment (see 4.3.6.7). However, it was found that all those 
patients who moved still remained within the catchment area served by the three TB 
clinics in Swakopmund district, so they could continue their treatment without 
interruption.  
In a study in Tijuana, Mexico mobility and migration were identified as important factors 
influencing TB treatment interruption (Deiss, Garfein, Lozada, Burgos, Brouwer, Moser, 
Zuniga, Rodwell, Ojeda & Strathdee 2009:1491–5).  
 
4.3.1.4  Formal educational level (Question A4)  
Only 105 (73.4%) respondents indicated their educational level when answering the 
questionnaires, and the results are reflected in Table 4.3.  
 
TABLE 4.3: FORMAL EDUCATIONAL LEVEL 
FORMAL EDUCATIONAL LEVEL NUMBER (N)  PERCENTAGE (%)  
None  6  5.7 
Primary  44  41.9 
Secondary  43  41.0 
Tertiary  12  11.4 
Total  105  100.0 
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In Namibia, primary level means grade 1 to grade 7, and secondary level means grade 
8 to grade 12. Most of the respondents’ educational level was primary level (44, or 
41.9%) and secondary level (43, or 41.0%) or below. Only a small percentage of TB 
patients had no school education (6, or 5.7%) or had tertiary education (12, or 11.4%). 
National data for Namibia indicates that 15% of Namibians have no education, 43% 
have primary education, 35.4% have secondary education and 4.8% have tertiary 
education (Namibia 2008a:10–11).  
 
A study done in Yemen (Date & Okita 2005:680–5) found that women were not 
prevented from accessing TB diagnosis and treatment even though they might lack 
formal education. The male relatives supported these women and were important in 
helping them achieve good treatment outcomes.  
 
Findings from a study in a rural TB unit in South India indicated that 39% of the 558 
non-adherent TB patients in a retrospective study were reported to be illiterate (Gopi, 
Vasantha, Muniyandi, Chandrasekaran, Balasubramanian & Narayanan 2007:66–70).  
 
4.3.1.5  Employment status (Question A5)  
Respondents were asked to indicate only whether they were employed or not. The 
employment status of the 103 (72.0%) who responded is indicated in Table 4.4.  
 
TABLE 4.4: EMPLOYMENT STATUS OF TB PATIENTS 
EMPLOYMENT STATUS NUMBER PERCENTAGE   (%)  
Employed  45  43.7 
Unemployed  58  56.3 
Total  103  100.0 
 
The results indicates a high level of unemployment (56,3%) among TB patients in the 
Swakopmund district. In the Erongo region, specifically, unemployment stood at 16.8% 
in males and 56% in females. Compared to the national data, the respondents in the 
study had a higher than average level of unemployment. Nationally, the level of 
unemployment in the 15 to 49 year age group is 37.6% (Namibia 2008a:35–6).  
 
In a case control study in Manila, Philippines, unemployment was found to be a 
significant factor predicting treatment completion. The Manila study was set in a 
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predominantly urban setting similar to the Swakopmund district (Lagrada, Uehara & 
Kawahara 2008:765).  
4.3.1.6  Income bracket (Question A6)  
Of the 143 respondents, only 97 (67.8%) provided data on their income bracket. The 
number of individuals per household was not taken into account. The income bracket 
classification of low, medium and high was based on the Republic of Namibia 2001 
population and housing census and was available at the end of the questionnaire for the 
field worker’s reference (Namibia 2003). Results are reflected in Table 4.5.  
 
TABLE 4.5: INCOME BRACKETS OF TUBERCULOSIS RESEARCH GROUP  
INCOME BRACKET NUMBER (N)  PERCENTAGE (%)  
Low (< N$400 per month)   52  53.6 
Medium (N$400–1500 per month)   39  40.2 
High (> N$1500 per month)   6  6.2 
Total  97  100.0 
 
Most of the respondents were in the low income bracket, with 53, 6% earning less than 
N$400 per month. In the survey, it was sad to note that of those that were employed, 
only six (6%) earned above N$1500 per month and more than half (52, or 53.6%) 
earned below N$400 per month.  
 
A cross-sectional study in a low-income area of Rio de Janeiro, Brazil, indicates that the 
provision of financial support to TB patients for food and transport leads to reduced 
treatment interruption. The financial support is especially helpful in the poor and 
marginalised TB populations (Belo, Seliq, Luiz, Hanson, Luna, Teixeira & Trajman 
2006:PH1–5).  
 
4.3.1.7  People sharing home with the patient (Question A7)  
This question (A7) was asked to determine with whom respondents stayed during the 
course of their TB treatment. This was an open-ended question and was analysed in a 
qualitative manner.  
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The respondents were staying either on their own or with any of the following: 
 
 a friend  
 mother  
 aunt  
 daughter  
 daughter’s son  
 alone  
 sister  
 uncle’s daughter  
 children  
 brothers  
 girlfriend  
 boyfriend  
 son  
 parents.  
 
Some stayed with a group of people, as indicated by the following responses: 
 
 my brother, his girlfriend and my children 
 grandmother and sisters  
 at a lodge with my children  
 husband and children  
 relatives 
 sister’s family  
 wife and children  
 mother and 3 brothers.  
 
Quite clearly, TB patients stayed with a variety of people and not only with close family. 
This question was included because the researcher reasoned that the way people took 
their medication could be influenced by who the patient stayed or lived with at home.  
 
The role of sufficiently trained family members for supporting TB patients in remote 
areas was noted  in a study in a study in Shaanxi province of China (Ai, Men, Guo, 
Zhang, Zhao, Sun, Zhang, He, Van der Werf & Van den Hof 2010:112). 
 
4.3.1.8  HIV status according to TB records (Question A8)  
For this question, the field worker had to consult the patient record in order to determine 
HIV status of the respondents. Respondents were therefore not asked directly about 
this. Of the 143 respondents, 138 (96.5%) had their HIV status recorded, and the results 
are reflected in Table 4.6.  
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TABLE 4.6: HIV STATUS OF TUBERCULOSIS RESEARCH GROUP  
HIV STATUS NUMBER (N)  PERCENTAGE (%)  
Positive  49  35.5 
Negative  52  37.7 
Unknown   37  26.8 
Total  138   100.0 
 
Of the patients with known HIV status, 49 patients (35.5%) had tested positive and 52 
(37,7%) negative. However, the HIV status of 37 (26.8%) of the respondents in this 
research group was unknown.  
 
The bigger picture looks as follows: the HIV prevalence in the Swakopmund district 
stood at 14.2% in 2008, and the national HIV prevalence rate in that year was 17.8% 
(Namibia 2008c:14).  
 
Of the 1470 new TB patients reported with TB in the Erongo region in 2008, 912 
(62.0 %) knew their HIV status. Four hundred and eighty eight TB patients in Erongo 
region tested positive which is 53.5%. Namibia tested 13737 TB patients in 2008 of 
which 66.9% knew their HIV status and 59% tested positive.  
 
The target HIV testing rate for TB patients in the country is set at 95% (Namibia 
2009a:14).  
 
In contrast to the findings in this study, a qualitative study in South Africa, which 
explored factors associated with TB treatment non-adherence, found HIV co-infection to 
be a contributory factor to treatment interruption (Naidoo et al 2009:55–70).  
 
4.3.2  Support (Section B)  
4.3.2.1  Completion of treatment (Question B1a)  
Of the 143 respondents, only 102 respondents revealed whether or not they had 




TABLE 4.7: TREATMENT INTERRUPTION AMONG PATIENTS IN THE STUDY  
TREATMENT INTERRUPTION NUMBER (N)  PERCENTAGE (%)  
YES (did not complete)   74  73.0 
NO (completed)   28   27.0 
TOTAL  102  100.0 
 
Only 28 (27%) of the TB patients took their medication without interrupting treatment; 
74 (73%) interrupted treatment. Treatment interruption, in this study, was defined as not 
taking medication for a cumulative seven days or more.  
 
This high rate of interruption or partial non-completion is also noted by Mateus-Solarte 
and Carvajal-Barona (2008:520–26), who noted a rate of 65.6% non-completion in Valle 
del Cauca in Columbia. The timing of patient default would be also be an important 
variable to investigate, though this variable was not analysed in the present study.  
 
4.3.2.2  People who influenced discontinuation of TB treatment (Questions B1b 
and B1c)  
To an extent, Questions B1b and B1c investigated the same issue, namely who it was 
that influenced patients in stopping their treatment. The first of the two questions was 
open-ended, and participants mentioned the same group of people listed in B1c. From 
the qualitative analysis, many of those indicating “other” said no one had influenced 
them to interrupt treatment. They had interrupted because they had felt better or they 
had been too busy to continue.  
 
All 74 respondents who indicated that they had interrupted treatment completed the 
second question (B1c), and the results are presented in Table 4.8.  
 
TABLE 4.8:  SOURCE OF INFLUENCE RELATED TO INTERRUPTION 
SOURCE  NUMBER (N)  PERCENTAGE (%)  
Friends  27  37.0 
Health care workers  13  17.0 
Relatives  2  3.0 
Other  32  43.0 




Of those who interrupted treatment, people who had influenced them ranged from 
friends (27, or 37%) and relatives (2, or 3%) to health care workers (13, or 17%) and 
“others” (32, or 43%). One respondent, for example, said her boyfriend had influenced 
the stopping of TB treatment. As in Question B1c, “other” often meant “no one”. 
 
It is alarming to note from this study that a number of TB patients were influenced by 
health workers to stop their treatment. This is important because health workers are 
noted to be in a power category in communities and are able to influence attitudes, 
beliefs and perceptions within a particular community. They are supposed to promote 
adherence.  
 
The stigma which may be attached to TB may influence adherence to TB treatment 
(Dodor & Afenyadu 2005:827–32).  
 
A qualitative study in Addis Ababa, Ethiopia, by Sagbakken et al (2008) using 50 
in-depth interviews indicated that treatment interruption was due to dynamic processes 
involving lack of financial and practical help from relatives. This help would have been in 
the form of food, encouragement and money for transport.  
  
The complexity and dynamism of the treatment interruption phenomena is further shown 
by a systematic review conducted by Munro et al (2007a:238). The review looks at 
7 184 citations and 44 articles between 1966 and February 2005 using predetermined 
inclusion criteria and identifies family, community and household support as important 
factors in determining treatment interruption.  
 
4.3.2.3  People who influenced resumption of TB treatment after disruption 
(Questions B1d and B1e)  
Similarly to the previous two questions, Questions B1d and B1e investigated who it was 
that influenced participants to resume their treatment (after stopping). The first of these 
two questions was open-ended. The same group of people listed in B1d was 
mentioned. The analysis indicated that the following were listed as people who 
influenced the resumption of treatment: 
 
 Family including Mother 




 Uncle’s daughter 
 Wife and relatives 
 Friends 
 Health workers 
 No one 
 Nurses at the Clinic 
 Employer  
 Volunteer.  
 
In some cases, more than one person was responsible for persuading the patient to 
continue treatment.  
 
Of the 74 respondents who disrupted treatment, only 41 responded to Question B1e. 
The results are presented in Table 4.9. 
 
TABLE 4.9:  PEOPLE INFLUENCING CONTINUATION OF TB TREATMENT 
AFTER DISRUPTION 
PERSON/S NUMBER (N)  PERCENTAGE (%)  
Relatives  23  56.0 
Health care workers  9  22.0 
Others  7  17.0 
Friends  2  5.0 
Total  41  100.0 
 
Those who continued with their TB treatment said they had been influenced to continue 
mostly by relatives (23, or 56%), health care workers (9, or 22%), and to a lesser extent 
by other factors (7, or 17%) and friends (2, or 5%). It could be that those who did not 
answer this question took the decision by themselves.  
 
TB patients with limited financial and practical help from relatives and friends 
experienced that the total costs of treatment exceeded their available resources while 
those who were supported were more likely to continue their treatment (Sagbakken et al 
2008:11).  
 
4.3.2.4  Visitation by health worker (Questions B2a and B2b)  
Of the 143 respondents, only 112 responded to the question on visitation, and from 
these valid cases descriptive statistics were calculated.  
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TABLE 4.10: VISITATION BY HEALTH CARE WORKER 
RESPONSE NUMBER (N)  PERCENTAGE (%)  
Yes  26  23.2 
No  85  75.9 
Don’t know  1  0.9 
Total  112  100.0 
 
A very low number 23 (23%) of the patients had been visited by a health worker while 
on TB treatment.  
 
The analysis of the question following this one showed that these people had been 
visited by TB clinic volunteers, nurses and a community counsellor; only in one instance 
was the frequency given as “2 times a week”. In two cases the health care workers were 
family members, for example, “wife, because she is a nurse” and “aunt, because she is 
a nurse”. TB clinic volunteers assist at TB clinics providing mainly DOT and other 
functions like provision of supplementary food. Community counsellors in the district 
provide mainly HIV counselling services.  
 
A community randomised trial in Ethiopia showed improved treatment success when 
health extension workers were utilised. These extension workers are particularly helpful 
in settings with reduced health care coverage and access (Datiko & Lindtjorn 
2009:5443).  
 
4.3.2.5  Learning about TB (Question B3a)  
Respondents were asked where they had learnt most about TB. A variety of answers 
were reported.  
 
The qualitative analysis revealed that respondents had heard about TB from a parent 
who had TB; sisters; through cellphone messages; at school, a clinic or health centre; 
books, newspapers and magazines, and even while in prison.  
 
4.3.2.6  Media helpful in understanding TB (Question B3b)  




TABLE 4.11:  MEDIA HELPFUL IN UNDERSTANDING TB 
MEDIA NUMBER (N)  PERCENTAGE (%)  
Radio  83  75.5 
TV  12  10.9 
Print  6  5.5 
Cellphone  3  2.7 
Other  6  5.5 
Total  110  100.0 
 
According to the respondents, the radio (83, or 75.5%) was the most helpful medium to 
teach them about TB, followed by television (12, or 10.9%), print media (6, or 5.5%), to 
a much lesser extent cell phones (3, or 2.7%) and “other” (6, or 5.5%).  
 
4.3.2.7  Exposure to TB messages in the media (Question B3c)  
This question, asking specifically about TB exposure in the media after starting TB 
treatment, was answered by 111 respondents.  
 
TABLE 4.12:  EXPOSURE TO MEDIA AFTER STARTING TB TREATMENT 
RESPONSE NUMBER (N)  PERCENTAGE (%)  
Yes  90  81.1 
No  20  18.0 
Don’t know  1  0.9 
Total  111  100.0 
 
Most of the respondents (90, or 81.1%) had been exposed to TB messages in the 
media after starting TB treatment. At the time of the study, various media were 
constantly putting out messages on TB as part of an ongoing media campaign.  
 
A study in India (Gupta, Gupta & Behera 2011:11–17) noted the importance of 
continuous health education through various media to emphasise the need for 
continuation of treatment despite early improvement in symptoms. 
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4.3.2.8  Media with TB messages specified (Question B3d)  
A bit of a discrepancy was picked up in this question, because 90 respondents indicated 
“yes” in the previous question, but two more, namely 92, answered this question.  
 
TABLE 4.13:  MEDIA WITH TB MESSAGES SPECIFIED 
MEDIA NUMBER (N)  PERCENTAGE (%)  
Radio  61  66.3 
TV  13  14.1 
Print  2  2.2 
Cellphone  10  10.9 
Other  6  6.5 
Total  92  100.0 
 
Of the respondents who were exposed to media it was mainly through radio (61, or 
66.3%) and television (13, or 14.1%) broadcasting. In addition to the above media, in 
the analysis done in a qualitative way, respondents had heard about TB from a father or 
mother who had TB, from a sister, through cellphone messages, school, clinic or health 
centre, books and newspapers, magazine, or while in prison.  
 
Information, education and communication (IEC) was recognised as an important 
component of a national TB control programme in a cross-sectional descriptive study in 
Delhi, India. This particular study states that IEC has an influence on treatment 
completion and treatment seeking. It targeted both patients and the general population 
(Sharma, Nath, Taneja & Ingle 2009:321–32). While radio was the most popular 
medium in Swakopmund, television was recognised as the most effective media 
approach in Delhi. The Delhi study further states that effective media choices should 
depend on the particular sub-population targeted.  
 
4.3.3  Reasons for and perceived consequences of stopping TB treatment 
4.3.3.1  Reasons for stopping TB treatment (Questions C1a and C1b)  
Questions C1a and C1b investigated reasons for stopping TB treatment. Question C1b 
provided specific reasons from which the respondents could select, but in Question C1a 
they could list their own reasons. Respondents gave a variety of reasons, among them: 
 
40 
 Running after boyfriend from Henties Bay to Arandis 
 Arrived at clinic after closure because of work 
 Stopped by friends, also drinking alcohol 
 Change of shifts at work causing me to miss the timetable 
 Employer came late and hence I failed to take treatment 
 Staying far at “DRC” squatter area 
 Feeling better after treatment 
 Not aware of time to complete 
 Wanted to be with boyfriend 
 Went to Keetmanshoop to visit boyfriend.  
 
From this section it is clear that there were more reasons than just those offered as 
options in the next question. What is interesting is that side effects were not mentioned 
in this section, but they were indicated as a reason in the next question (Question C1b).  
 
Of the 74 treatment interrupters, only 34 selected reasons from those offered in 
Question C1b as to why they had stopped their TB treatment. The remaining 40 
respondents who interrupted treatment did not answer the question, or their responses 
were not recorded. Table 4.14 reflects the results.  
 
TABLE 4.14:  REASONS FOR HAVING INTERRUPTED TREATMENT 
REASON NUMBER (N)  PERCENTAGE (%)  
Lack of physical access  1  2.9 
Lack of family support  1  2.9 
Side effects  6  17.6 
Co-morbidity  1  2.9 
Lack of knowledge  9  26.5 
Work related issues  3  8.8 
Mobility and migration  11  32.4 
Other  2  6.0 
Total  34  100.0 
 
Interestingly, the most important reasons cited for stopping TB treatment were mobility 
and migration (11, or 32.4%), lack of knowledge (9, or 26.5%), side effects (6, or 17.6%) 
and work-related issues (3, or 9.0%). Lack of a physical access, lack of family support, 
co-morbidity and other reasons constituted the remainder (14.7%). The researcher 
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picked up that some of the addresses changed during the treatment, but they were still 
in the same treatment area (see 4.3.1.3). No respondents marked the following 
responses: lack of financial access (No. 2), beliefs and perceptions (No. 7) and 
programmatic factors and incentives (No. 10).  
 
4.3.3.2  Reasons why TB treatment should be continued (Question C2a)  
In answer to the question, “Why do you think you need to continue to take TB treatment 
for six months?”, the following responses were given: 
 
 to be healed  
 to avoid the sickness getting worse  
 so that she can be healthy to live for the children 
 don’t know  
 to be cured and not infect others.  
 
From these responses it is clear that not all participants understood why they needed to 
complete their treatment.  
 
4.3.3.3  Consequences of stopping TB treatment (Question C2b)  
Of 143 respondents, 106 answered this question on the most important perceived 
consequences of stopping TB treatment.  
 
TABLE 4.15:  PERCEIVED CONSEQUENCES OF STOPPING TB TREATMENT 
CONSEQUENCE NUMBER (N)  PERCENTAGE (%)  
Nothing  8  7.5 
Will become more sick  24  22.6 
Death  58  54.7 
Transmission to others  8  7.5 
Multi-drug resistance  6  5.7 
Other  2  1.9 
Total  106  100.0 
 
According to the respondents, the most important consequences of stopping TB 
medicines were death (58, or 54.7%), becoming more sick (24, or 22.6%), transmission 
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to others (8, or 7.5%), and multi-drug resistance (6, or 5.7%). A few respondents felt 
that “nothing happens” (8, or 7.5%).  
 
Health promotion theories such as the health belief model refer to consequences of a 
condition having an influence on behaviour. This is also largely dependent on the 
person’s environment (Nutbeam & Harris 2004:10–23). Respondents in the study did 
perceive themselves to be at risk of serious consequences as a result of treatment 
interruption. Despite this, 73% of respondents in this study interrupted their treatment.  
 
4.3.4  DOTS 
4.3.4.1  Location where TB treatment had been taken initially (Question D1a)  
The data for this question could not be used, as it was clear that respondents had 
misunderstood the question.  
 
4.3.4.2  Location where TB treatment had been taken recently (Question D1b)  
Again, the data for this question could not be used, respondents had clearly 
misunderstood the question.  
 
4.3.4.3 Preferred location for taking TB treatment (Question D1c)  
Question D1c asked the respondents to indicate where they would prefer to take their 
treatment, because this could be a factor in promoting adherence. Of the 143 
respondents, only 108 answered the question.  
 
TABLE 4.16:  PREFERRED LOCATION FOR TAKING TB TREATMENT 
LOCATION NUMBER (N)  PERCENTAGE (%)  
Home  69  63.9 
Health centre  26  24.1 
Hospital  11  10.2 
Other  2  1.8 
Total  108  100.0 
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The majority of respondents preferred to take their TB treatment at home (69, or 64%), 
at a health centre (26, or 24, 1%), hospital (11, or 10.2%) and other location (2, or 
1.8%).  
 
A comparative cohort study in the Omaheke region of Namibia shows a preference for 
community-based treatment. Family members are regarded as best placed to provide 
DOT to patients. Better cure rates were achieved in patients who had the community-
based approach. However, the authors note that it is not possible to establish a causal 
link between the community-based approach and the outcome of better cure rates 
(Zvavamwe & Ehlers 2009:302–9).  
 
4.3.4.4 Supervision of taking medicines by a second person (Question D2a)  
Only 97 respondents answered this question on status of supervision by a second 
person.  
 
TABLE 4.17:  SUPERVISION BY A SECOND PERSON 
SUPERVISION FREQUENCY (N)  PERCENTAGE (%)  
Yes  68  70.1 
No  21  21.6 
Don’t know  8  8.2 
Total  97  100.0 
  
Most of these respondents (68, or 70.1%) had been supervised each time they took 
their TB treatment.  
 
DOT is a strategy that is used by many national TB programmes. A study in Thailand 
actually concluded that DOT was the only modifiable factor associated with defaulting of 
TB treatment. This was an observational cohort study under programmatic conditions. 
After controlling for the likelihood of being assigned to DOT, those not assigned to DOT 
remained with an increased risk of default (Kapella, Anuwatnonthakate, Komsakorn, 




4.3.4.5  Other person supervising the taking of medicines (Question D2b)  
According to the strict definition, DOT is provided by an independent and trained health 
worker. In the survey, respondents were asked to answer whether a second person 
supervised them taking medication. If they answered yes, they were then asked to give 
details regarding the supervision.  
 
This was an open-ended question and was therefore analysed in a qualitative manner. 
Descriptions of those who supervised and how they supervised the taking of TB 
medicines included: 
 
 Nurse and friend  
 Mother giving food and tablets 
 Aunt cooking food and giving 
tablets 
 Nurse and aunt  
 Sister  
 Daughter  
 Volunteer  
 Uncle’s daughter 
 No supervision the patient takes 
tablets on his own 
 My children and health workers 
 Wife and children 
 Sister and daughter 
 Mother, health workers and 
community counsellors 
 My brother, a DOT health worker  
and community counsellors 
 Grandmother and health workers 
 Doctor 
 Employer 
 Boyfriend  
 Health care workers and volunteers  
 Nurses at the clinic  
 No one 
 Nurse and girlfriend.  
 
From the above it is evident that the supervision of TB treatment in the district is not 
limited strictly to trained, independent observers. A variety of people or combinations of 
people assisted.  
 
It is important to note that the ethical and legal obligation to ensure treatment 
completion lies with the health system and community, not with the individual patient 
(Frieden & Sbarbaro 2007:30-33).  
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4.3.4.6  Perception of being supervised in taking medicines (Question D2c)  
This question was also an open-ended question and was analysed in a qualitative 
manner.  
 
Respondents’ feelings regarding being supervised in taking medicines were mostly 
positive, as follows:  
 
 Feel it is fine and have no problem with that  
 Very very good  
 Very important since sometimes one forgets to take the tablets at home.  
 
No very specific negative responses were recorded.  
 
4.3.5  Medication and side effects 
4.3.5.1  Side effects experienced on TB medicines (Question E1a)  
The first question in this section (E1a) was open-ended and asked the respondents 
about the effect of the medication on them. It was analysed in a qualitative manner.  
 
Respondents’ answers included the following: 
 
 Red pill caused dizziness, sweating and nausea 
 Painful legs and swelling of feet 
 No side effect 
 Change of urine at the beginning 
 Itching  
 Nausea and vomiting 
 Heart beating excessively  
 Headache 
 Weakness 
 Skin rash and vomiting 
 Sore hands  
 Joint pains.  
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The reported side effects are all in line with known side effects to first-line anti-TB 
medication. Rifampicin is the medicine referred to as the “red pill” above and is known 
to cause nausea, dizziness and sweating (Namibia 2006a:48).  
 
4.3.5.2  Action taken after experiencing side effects (Question E1b)  
Question E1b was also open-ended and analysed in a qualitative manner. Respondents 
mentioned the following (among others) as actions taken because of the effects: 
 
 consulting the nurses 
 seeing the doctor 
 did nothing 
 continued on medication 
 came to the clinic 
 Rest a bit then resume after a while as I feel better 
 went to the hospital  
 consulted boyfriend.  
 
The tendency was to consult with someone, in many cases a health care professional.  
 
4.3.5.3  Person informed about the medication problems (Question E2a)  
This open-ended question gave the respondent the opportunity to mention any person 
that they informed, and responses included the following: 
 
 the doctor  
 Nurses  
 No one  
 TB Volunteer  
 sisters.  
 
It is interesting to note that family members were not mentioned here. It therefore 
seems as if the persons trusted with this information had something to do with the 
health system.  
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4.3.5.4  Action taken by person informed of medication problems  
 (Question E2b)  
Again an open-ended question was asked, so that the respondents themselves could 
indicate what actions were taken. Responses included the following: 
 
 Referred to the doctor but did not go to the doctor 
 treated with pain medication  
 did not do anything  
 Motivated by the doctor to see a nurse after the week  
 given medication.  
 
Minor and major side effects are managed according to Namibian TB treatment 
guidelines (Namibia 2006a:48).  
 
4.3.5.5  Most unwanted side effects of TB medicine (Question E3)  
In this item the respondents had to choose, from a given list, the worst side effect they 
had experienced. Of the 143 respondents, 33 reported experiencing side effects.  
 
TABLE 4.18:  MOST UNWANTED SIDE EFFECTS OF TB MEDICINE 
SIDE EFFECT NUMBER (N)  PERCENTAGE (%)  
Skin problems  6  18.2 
Yellow eyes  4  12.1 
Nausea and vomiting  11  33.3 
Joint/limb pains  4  12.1 
Dizziness and headaches  3  9.1 
Other  5  15.2 
Total  33  100.0 
 
The most unwanted side effects from TB treatment were nausea and vomiting (11, or 
33.3%), skin problems (6, or 18.2%), joint/limb pains (4, or 12.1%), yellow eyes (4, or 
12.1%) and dizziness and headaches (3, or 9.1%). The other side effects made up the 
remaining 5 responses (15.2%).  
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A study in new Dehli noted side effects during DOTS as nausea and vomiting (53%), 
aches and pains (27%), skin rash (17%), arthralgia (11%)and hepatotoxicity (1%). The 
majority of these side effects occurred in the first four weeks of treatment. In this study 
only 0.25% of patients treated under DOTS had interrupted for short periods (Dhingra, 
Rajpal, Aggarwal, Aggarwaln, Shadab & Jain 2004:251–9). 
 
4.3.6  Access to TB treatment 
4.3.6.1  Problems experienced on receiving TB medicines on a monthly basis 
(Question F1a)  
The section on access to TB medicine started with an open-ended question (F1a) about 
the biggest problem experienced while getting TB medicines.  
 
The following responses were obtained when analysed in a qualitative manner: 
 
 No problem 
 When she could not go to the clinic, she sent someone else who was ill-treated by 
nurses at the clinic 
 Because of work, he has no one to send to the clinic for the checkups and 
medication 
 Staying far in DRC informal settlement 
 The work because of late shifts 
 Place is too far and no food 
 At the beginning of travelling, I feel very weak 
 Tired, but because of my health, I go  
 Money for hitch hiking 
 Make her tired weak 
 Only allowed to take them for a few day 
 During holidays when clinics may be closed and I forget 
 sometime find the clinic close 
 busy and hence forget to take time 
 too weak to go to the clinic 
 Tired and very weak 
 Wasting.  
 
49 
From these responses it is clear that many problems were experienced by these 
patients who had to get medication on a monthly basis. These are mostly problems that 
can be solved. From some of the responses it seems that distance was problematic for 
some respondents. Community-based care has been noted to improve access to TB 
treatment. It is recognised that successful initiatives are built on community knowledge, 
input and motivation, and not centralised health care bureaucracy (WHO 2008).  
 
4.3.6.2  Cost of getting to the health centre monthly (Question F1b)  
Only 82 respondents answered this question on their travelling costs for treatment. The 
cost of travelling is reflected in Table 4.19.  
 
TABLE 4.19:  PATIENTS’ COSTS OF TRAVELLING TO HEALTH FACILITY IN 
SWAKOPMUND DISTRICT  
 N RANGE MINIMUM MAXIMUM MEAN STD DEVIATION 
Cost (N$)  82 290 0 290 16.8 54.5 
 
Monthly travelling costs to get to the health centre ranged from N$0 to N$290, with a 
mean monthly cost of N$16.83 and a standard deviation of N$54.49. For people without 
an income this amount can be a lot of money.  
 
A qualitative study in Gambia showed that, regardless of the gender of the TB patient, 
problems related to transport affordability led to reduced access to TB treatment 
(Eastwood & Hill 2004:70–75).  
 
4.3.6.3  Time taken from home to health centre and back (Question F1c)  
In this question, the participants were asked how long it took for them to get their TB 
treatment. A hundred and two respondents out of 143 answered . 
 
TABLE 4.20:  TIME TO GET TB TREATMENT 
 N RANGE MINIMUM MAXIMUM MEAN STD DEVIATION 
Time (min)  82 295 5 300 62.42 58.1 
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The time taken to travel to the health centre, receive treatment, and travel back home 
ranged from 5 minutes to 5 hours (300 minutes), with a mean of 62.4 minutes and a 
standard deviation of 58.1 minutes.  
 
Around an hour once a month is not much time to get medication, and if this is a true 
reflection of the current situation, it could be used as a positive factor to motivate 
patients to access medication. They could be told that on average it should take just 
over an hour to get it.  
 
4.3.6.4  Perception of travelling cost to health centre (Question F2)  
The monetary price of anything is a relative concept in any situation: each person 
interprets it in terms of his or her income or wealth. The respondents were therefore 
asked in Question F2 whether they considered the travelling to be expensive or not. 
This question was answered by 94 respondents.  
 
TABLE 4.21:  PERCEPTION OF COST 
PERCEPTION NUMBER (N)  PERCENTAGE (%)  
Not expensive  76  73.1 
Expensive  15  14.4 
Very expensive  13  12.5 
Total  104  100.0 
  
The cost of travelling to the health centre was generally regarded as “Not expensive” by 
most respondents (60, or 73.1%).  
 
4.3.6.5  Means of transport used to get to TB clinic (Question F3)  
The participants were asked to indicate their means of transport, and 97 responded to 
the question. Results are reflected in Table 4.22.  
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TABLE 4.22:  MEANS OF TRANSPORT 
MEANS OF TRANSPORT NUMBER (N)  PERCENTAGE (%)  
Foot  87 81.3 
Bicycle  4   3.7 
Taxi  15   14.0 
Other  1   0.9 
Total  107  100.0 
  
Of note is that there were no respondents who used a donkey cart or employer’s car.  
 
The most popular means of transport to the TB clinic was on foot (87, or 81.3%), which 
explains why most did not consider the travelling cost to be high.  
 
4.3.6.6  Estimated distance between home and health centre (Question F4)  
The respondents had to indicate their distance from the health care centre, choosing 
one of five options. The results of 108 respondents that answered are reflected in Table 
4.23. 
 
TABLE 4.23:  ESTIMATED DISTANCE BETWEEN HOME AND HEALTH CENTRE 
DISTANCE (KM)  NUMBER (N)  PERCENTAGE (%)  
0–5  100  92.6 
6–10  8  7.4 
11–15  0  0.0 
16–20  0  0.0 
More than 20  0  0.0 
Total  108  100.0 
 
The majority of patients (100, or 92.6%) lived less than 5 km from the health centre.  
 
A cohort study in Ethiopia (Shargie & Lindjorn 2007:37), using predetermined risk 
factors that were followed up, shows that the need to use public transport and the 
distance from home to the treatment centre are associated with treatment interruption. 
In the Ethiopian study, physical access to the treatment centre is a factor independently 
associated with treatment interruption. In Swakopmund, however, it is important to note 
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that almost all patients (81.3%) accessed the health centre on foot and did not rely on 
public transport. The majority (92.6%) were living within 5 km of the health facility.  
 
4.3.6.7  Change of address during TB treatment (Questions F5, F6 and F7)  
Questions F5 and F6 specifically asked participants what their addresses were when 
they started and when they discontinued TB treatment. However, the issue of 
importance here, and asked directly in Question F7, is whether the respondent’s 
residence changed during the course of TB treatment. This question was answered by 
104 participants.  
 
TABLE 4.24:  CHANGE OF PLACE OF RESIDENCE DURING TB TREATMENT 
CHANGE OF RESIDENCE NUMBER (N)  PERCENTAGE (%)  
Yes  21  20.2 
No  83  79.8 
Total  104  100.0 
 
Most of the patients (83, or 79.8%) had not changed their place of residence during TB 
treatment.  
 
4.3.7  Patient–provider relationship 
4.3.7.1  Problems experienced during clinic attendance (Question G1)  
This open-ended question enquired in a general way about problems experienced in 
attending clinics. The responses were analysed in a qualitative manner and included the 
following: 
 
 No problems 
 Busy and unwell at home, therefore sending brother who later refused to go 
 Work pressures 
 Too far and age too old to walk (58 years)  
 No money to get a taxi 
 Employer threatens to fire 
 Arriving late from work 
 Taking treatment from the hospital  
 Injured on leg and cannot walk long distance.  
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The problems reported as experienced by individuals varied from person and did 
include responses that indicated that the clinic was far or that the hours were not 
convenient.  
 
4.3.7.2  Preferred clinic opening times (Question G2)  
Respondents could choose between five options of suggested clinic opening hours. A 
total of 112 respondents answered the question and the results are reflected in Table 
4.25.  
 
TABLE 4.25:  PREFERRED CLINIC OPENING TIMES 
OPENING TIME NUMBER (N)  PERCENTAGE (%)  
Earlier than 8 am and up to 5 pm  86  76.8 
8 am to 5 pm  23  20.5 
Earlier than 8 am until later than 5pm  2  1.8 
Other  1  0.9 
Total  112  100.0 
 
The most popular clinic opening times were “Earlier than 8 am and up to 5 pm”, chosen 
by 76.8% of the respondents. Actual clinic opening times in this research setting were 
from 8 am to 5 pm. This time opening was thus not in line with the preference of the 
majority of respondents.  
 
The rigidity of clinic opening times increases barriers to accessing TB treatment. This is 
supported by a qualitative study in Ethiopia, where it was found that the problems of 
access due to a lack of financial and practical help were reinforced by rigid clinic 
opening times (Sagbakken et al 2008:11).  
 
4.3.7.3 Preferred opening days (Question G3)  
Respondents were given a choice of three options to indicate their preferred TB clinic 




TABLE 4.26:  PREFERRED OPENING DAYS 
OPENING DAYS NUMBER (N)  PERCENTAGE (%)  
Monday to Friday  88  80.0 
Monday to Friday 
plus weekends 
 21  19.1 
Special days for TB   1  0.9 
Total   110   100.0 
 
The most popular opening days were “Monday to Friday” (88, or 80%). Clinics in the 
research setting operated from Monday to Friday. About 20% of the respondents 
preferred other opening days.  
 
4.3.7.4  Reception experienced at TB Clinic (Question G4)  
The final question in this section gave respondents the opportunity to describe the 
reception they got at the TB clinic. They had a choice of three options. This question 
was answered by 110 respondents. The results are reflected in Table 4.27.  
 
TABLE 4.27: RECEPTION EXPERIENCED AT HEALTH CENTRES 
RECEPTION NUMBER (N)  PERCENTAGE (%)  
Friendly  103  93.6 
Unfriendly  2  1.8 
Indifferent  5  4.5 
Total  110  100.0 
 
The majority of respondents (103, or 94%) indicated that they experienced the reception 
as friendly.  
 
A case control study in a hilly Western district of Nepal (Mishra et al 2005:1134–9) 
found poorly graded communication between the patients and dispensers to be a 
significant factor in causing treatment interruption. A survey in Pakistan found provider 
attitudes to be poor, with health care workers expressing unsupportive views (Khan, 
Walley, Witter, Shah & Javeed 2005:354–65). The negative attitude of health workers is 
also noted in a qualitative study in Southern Nigeria, where health workers demanded 
money from TB patients for a service which was advertised as free, and also showed a 
hostile attitude (Okeibunor, Onyeneho, Chukwu & Post 2006:23–27 54).  
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4.3.8  Stigma 
4.3.8.1  Feelings with regard to sharing TB diagnosis with others (Question H1)  
This open-ended question investigated disclosure of a particular diagnosis, in this case 
TB. Responses were analysed in a qualitative manner and were as follows: 
 
 No problem  
 Felt better with aunt and not boyfriend  
 Friends; family and church members  
 Bad; Very bad because the community thought that I had AIDS 
 Some people do not know the difference between STD and TB  
 Feel very embarrassed because people will think that they have AIDS 
 Difficult 
 Relief  
 Family and friends  
 Ashamed to tell people the TB results  
 Not easy, except the family members.  
 
From these responses it seems that disclosure could be a problem for patients in this 
research context. Experience of stigma was noted to be common and might have 
contributed to treatment interruption. For effective TB control, closer attention must be 
paid to stigma (Abioye, Omotayo and Alakija 2011:S100–04).  
 
4.3.8.2  Persons informed by patient about TB diagnosis (Question H2)  
Following the disclosure question above, an open-ended question was asked (H2) to 
determine whom the respondents were able to tell that they were suffering from TB.  
 
Responses were analysed in a qualitative manner and included the following: 
 
 Friends and relatives 
 Mother and friends 
 Aunt 
 Relatives at home and in the south  
 Uncle and his wives  
 Family and friends 
 Wife  
 My children and friends 
 Grandmother and aunts  
 Friends  
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 Anyone in the community 
 Several mentioned Sister  
 Mother and Brother  
 No-one  
 Brother  
 Family members 
 friends and managers  
 Husband  





These examples show that patients had informed a variety of individuals, or groups of 
individuals.  
 
4.3.8.3  Friends/relatives informed about TB diagnosis (Question H3)  
Respondents were asked to indicate if they informed a friend or a relative about the 
diagnosis (Q H3), and 109 completed the question. The results are reflected in Table 
4.28.  
 
TABLE 4.28:  DISCLOSURE OF TB STATUS TO FRIEND/RELATIVE  
INFORMED NUMBER (N)  PERCENTAGE (%)  
Yes  108  99.1 
No  1  0.9 
Total  109  100.0 
 
Most of the respondents (108, or 99.1%) informed their friends or relatives about the TB 
treatment, as was clear from the previous section (4.3.8.2).  
 
In a study in Jogjakarta, Indonesia, it was noted that patients sought advice from family 
and friends, and this influenced their care-seeking behaviour (Rintiswati, 
Mahendradhata, Suhama, Susulawati, Purwanta, Subronto, Varkevisser & Van der Werf 
2009:158).  
4.3.8.4  Reasons for not informing friends/relatives about TB diagnosis 
(Question H4)  
Respondents who indicated that they did not tell friends and family about their TB 
diagnosis were asked to choose one of three possible reasons (Q H4).  
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The respondent who did not tell friends and relatives feared a negative response from 
those close to him.  
 
4.3.8.5  Form of assistance received from friends/relatives (Question H5)  
Respondents were asked to indicate if assistance or support had been received from 
family members or friends (Question H5). Four options were available to choose from. 
Results from the 97 respondents who completed this question are reflected in Table 
4.29.  
TABLE 4.29:  FORMS OF ASSISTANCE RECEIVED BY TB PATIENTS 
ASSISTANCE NUMBER (N)  PERCENTAGE (%)  
Food  72  74.2 
Money  11  11.3 
Other  14  14.4 
Total  97  100.0 
 
Assistance from relatives and friends was in the form of food (72, or 74.2%), money (11, 
or 11.3%), and other forms of practical help (14, or 14.4%).  
 
Transport was not mentioned by any respondent, and in the light of section 4.3.3.6 it is 
not surprising, since it was found that the majority of respondents in this study context 
stayed fairly close to the TB clinics.  
 
4.3.8.6  Employee disclosure of TB diagnosis to employer (Question H6)  
Respondents were specifically asked if their TB diagnosis had been disclosed to their 
employers (Question H6). Only 70 respondents answered this question, and the results 
are reflected in Table 4.30.  
 
TABLE 4.30:  DISCLOSURE OF TB STATUS TO EMPLOYER  
DISCLOSURE NUMBER (N)  PERCENTAGE 
(%)  
Yes  58  82.9  
No  12  17.1 
Total  70  100.0 
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Most of the respondents (58, or 82.9%) told their employer about their TB treatment, 
and some were able to access TB treatment at work. In a study in South Africa, public–
private workplace partnerships were found to have the highest quality of care compared 
to public sector TB clinics and non-governmental organisation community-based TB 
care. This was noted to be particularly crucial where the public sector did not have the 
capacity to monitor the quality of care of TB patients (Sinanovic & Kumaranayake 
2006:795–801).  
 
4.3.8.7  Reasons for not disclosing TB diagnosis to employer (Question H7)  
The respondents who did not tell their employer about the TB diagnosis were requested 
to indicate the reason for not doing so (Question H7). They had four options to choose 
from. Of the 12 respondents who had answered negatively in the previous question, 
only seven answered this question. Responses are reflected in Table 4.31.  
 
TABLE 4.31:  REASONS FOR NOT DISCLOSING 
REASON NUMBER (N)  FREQUENCY (%)  
Fear of losing job  1  14.3 
Fear of isolation at work  2  28.6 
Other  4  57.1 
Total  7  100.0 
 
Those who did not disclose to employers either feared isolation at work (2, or 28.6%), 
feared losing their jobs (1, or 14.3%) or had other unstated reasons (4, or 57.1%).  
 
A study in Addis Ababa, Ethiopia, noted that lack of employment, or the possibility of 
getting work, led to various interrelated barriers for TB patients (Sagbakken et al 
2008:11). 
 
4.3.9  Substance use 
4.3.9.1  Cigarette smoking (Question I1a)  
The first question (I1a) in this section investigated whether the respondents were 
smokers or not. The question was answered by 97 respondents and the results are 
reflected in Table 4.32.  
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TABLE 4.32:  PATIENTS WHO SMOKE 
SMOKER NUMBER (N)  PERCENTAGE (%)  
Yes  23  23.7 
No  74  76.3 
Total  97  100.0  
 
The majority of patients in this study did not smoke.  
 
4.3.9.2  Cigarette smoking during prior seven days (Question I1b)  
The second question (Question 1b) determined if any respondent had smoked in the 
past seven days. This question was answered by 92 respondents, and results are 
reflected in Table 4.33.  
 
TABLE 4.33:  SMOKING DURING PAST SEVEN DAYS 
SMOKING NUMBER (N)  PERCENTAGE (%)  
Yes  23  25.0 
No  69  75.0 
Total  92  100.0  
 
The majority of patients had not smoked during the past seven days.  
 
4.3.9.3  Period taken to smoke a pack of 20 cigarettes (Question I1c)  
The third question (I1c) asked how long a smoker generally took to smoke a pack of 20 
cigarettes. This question was answered by 20 out of the 23 smokers, and the results are 
reflected in Table 4.34.  
 
TABLE 4.34:  PERIOD TO SMOKE A PACK OF 20 CIGARETTES 
 N RANGE MINIMUM MAXIMUM MEAN STANDARD 
DEVIATION 
Period to smoke 20 
cigarettes (days)  
20 28 2 30 7.6 6.1 
 
For those who smoked, a packet of 20 cigarettes lasted a minimum of two days and a 
maximum of 30 days, with a mean of 7.6 days and a standard deviation of 6.1 days.  
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4.3.9.4  Alcohol consumption (Question I2a)  
The first question determined whether a respondent consumed alcohol or not. This 
question was answered by 107 respondents and the results are reflected in Table 4.35.  
 
TABLE 4.35:  ALCOHOL CONSUMPTION 
ALCOHOL CONSUMED NUMBER (N)  PERCENTAGE (%)  
Yes  34  31.8 
No  73  68.2 
Total  107  100.0  
 
The majority (73, or 68.2%) indicated that they did not consume alcohol.  
 
4.3.9.5  Consumption of alcohol in past week (Question I2b)  
The second question asked if any respondent had consumed alcohol in the past seven 
days. This question was answered by 88 respondents and the results are reflected in 
Table 4.36.  
 
TABLE 4.36:  ALCOHOL CONSUMPTION IN THE PAST WEEK 
ALCOHOL CONSUMED NUMBER (N)  PERCENTAGE (%)  
Yes  17  19.3 
No  71  80.7 
Total  88  100.0  
 
Seventeen (19.3%) of the respondents reported having consumed alcohol in the 
previous week.  
 
4.3.9.6  Quantity of alcohol consumed in the past week (Question I2c)  
Question I2c determined the amount of alcoholic drink, in pints, taken by a respondent. 




TABLE 4.37:  QUANTITY OF ALCOHOL CONSUMED IN THE PAST WEEK 
 N RANGE MINIMUM MAXIMUM MEAN STD DEVIATION 
In the last week, how  
many pints of alcohol  
have you consumed? 
17 6 0 6 2.4 1.9 
 
Of those who had drunk alcohol in the last week, consumption in pints ranged from 0 to 
6 pints, with an average of 2.4 pints and a standard deviation of 1.9 pints. Where 
alcoholic drinks other than beer were consumed, the equivalent amount of alcohol in 
terms of pints of beer was estimated.  
 
4.4  OVERVIEW OF RESEARCH FINDINGS 
The average age of participants was 35.7 years, with a predominance of male 
participants (65%). Most of the respondents were unemployed (56.3%) and in the low 
income bracket (53.6%). From the study, 35.5% of the respondents were HIV positive, 
while the HIV status of 26.8% was unknown.  
 
Very few of the respondents had reached a tertiary level of education (11.4%), while 
5.7% had no formal education.  
 
A total of 73% of the respondents interrupted their treatment for seven days or more. 
Mobility, lack of knowledge, and treatment side effects were the most important reasons 
for 34 of the 74 participants who interrupted treatment. Friends were most influential in 
causing discontinuation of treatment, while relatives were most influential in supporting 
continuation after disruption. 
 
Only 23.2% of the respondents were visited by health care workers during their 
treatment.  
 
Most of the respondents (81.1%) were exposed to some form of media, and the radio 
was the most popular of the media (75.5%).  
 
Respondents cited death as the most feared adverse outcome of treatment interruption.  
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Most respondents preferred DOT at home (63.9%), and 70.1% indicated that they did 
not mind being supervised by a second person during treatment. The reception at the 
clinics was regarded as friendly by most respondents (93.6%). The respondents 
preferred the clinic to open before 8 am and remain open until 5pm from Monday to 
Friday.  
 
Nausea and vomiting was the major side effect of TB treatment reported.  
 
The average monthly cost of treatment was N$16.83, and most regarded this as “Not 
expensive” (73.1%). The low cost could be ascribed to the fact that most respondents 
(81.3%) went to the TB clinic on foot. The majority of respondents did not change their 
place of residence during treatment, and those who did move still remained within the 
district.  
 
The majority of respondents (99%) disclosed their TB status to relatives and friends.  
 
Some respondents consumed alcohol (19%) and smoked (25%) during the seven days 
prior to the survey.  
 
4.5  CONCLUSION 
The majority of respondents in the study interrupted their TB treatment for seven days 
or more. The significance of different factors possibly influencing treatment interruption 
is reported in Chapter 5.  
63 
CHAPTER 5 
CONCLUSION AND RECOMMENDATIONS 
5.1  INTRODUCTION 
The purpose of the study was to investigate and identify factors associated with the 
interruption of TB treatment in Swakopmund district, Erongo Region, Namibia. The 
researcher undertook a cross-sectional study by which he investigated and identified 
the reasons why patients interrupted TB treatment in the study context, and was thus 
able to achieve the objective of the study. 
 
This study was essential because TB treatment interruption is related to adverse 
outcomes such as the development of drug resistant strains of mycobacterium 
tuberculosis (MTB) and ultimately death. An understanding of treatment interruption and 
its determinants is further essential to assist in designing effective interventions to limit 
mortality and morbidity and the development and spread of drug resistant TB.  
 
This chapter summarises and discusses the findings. The chi-square statistic (χ
2
), 
degrees of freedom (df) and p value will be reported where applicable.  
 
5.2  STUDY FINDINGS 
5.2.1  Respondents socio-demographic factors 
5.2.1.1  Influence of age 
The average age of participants was 37.5 years. Ages of participants ranged from 15 
years to 76 years. TB in Swakopmund district affected a wide age group. Globally 
around two thirds of TB cases are noted to occur in the 15–59 year age group (WHO 
2011:3).  
 
5.2.1.2  Influence of gender 
The majority of TB patients in the study, namely 65%, were male. National TB data 
indicated that 58% of all new smear positive TB patients in Namibia are male. The 
predominance of males over females in the study is therefore consistent with national 
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data. Globally, it has also been noted that TB is more common among men than women 
(WHO 2011:3).  
 
5.2.1.3  Patient address 
The study showed that although patients moved and changed addresses during their 
TB treatment, all remained within the catchment area of the district.  
 
5.2.1.4  Influence of educational level 
While most of the TB patients had received primary and secondary education, very few 
(11.4%) had been exposed to tertiary education. This finding is consistent with national 
data which shows that only 4.8% of Namibians have tertiary education (Namibia 
2008a:10–11).  
 
There was a significant association between treatment interruption and level of 
education. χ
2
 = 13.81, df = 6, p = 0.032. A study in Ndola, Zambia (Kaona, Tuba, Siziya 
& Sikaona 2004:68) found educational level not to be significantly associated with 
treatment interruption. Factors that were found to be related to non-compliance in this 
study were feeling better, lack of knowledge, running out of drugs at home and TB 
drugs which were too strong.  
 
Educational status was found to be negatively correlated with drug resistant TB in a 
study in south East Turkey (Tanrikulu, Hosoglu, Ozekinci, Abakay & Gurkan 2008:91–
3). Drug resistance is a possible outcome of treatment interruption.  
 
5.2.1.5  Influence of employment status 
TB patients in Swakopmund District showed a much higher rate of unemployment 
(56.3%) than the general population in Namibia (37.6%). In the study, employment 
status was not significantly associated with treatment interruption. χ
2
 = 0.855, df = 2, 
p = 0.652.  
 
In a case control study in Manila, Philippines, unemployment was found to be a 
significant factor in predicting treatment completion. The Manila study was set in a 
predominantly urban setting similar to that of Swakopmund (Lagrada et al 2008:765).  
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5.2.1.6  Influence of income bracket 
The study showed that most of the TB patients were in the low income bracket, earning 
less than N$400 per month. This particular contextual study suggests that the poorer 
sector of the population is more vulnerable to TB than are the richer groups. 
 
Income bracket, surprisingly, was not a significant factor associated with treatment 
interruption: χ
2
 = 0.792, df = 4, p = 0.940. Findings of a study in Addis Ababa, Ethiopia, 
indicate that long-term lack of income is related to treatment interruption, especially in 
the later stages of the TB treatment (Lagrada et al 2008:765, Sagbakken et al 2008:11).  
 
5.2.1.7  Influence of people sharing home with the respondent 
TB patients in the study stayed with a wide variety of people during their treatment. It is 
not possible to say, from this study, whether the people one stays with have any 
significant influence on treatment interruption or not.  
 
5.2.1.8  Influence of HIV status 
The percentage of patients who tested HIV positive was 35.5% (49), while 37.7% (52) 
tested negative. In the research group, 26.8% (37) of the respondents had an unknown 
HIV status. HIV status had no influence on TB treatment interruption in this study. 
χ
2
 = 3.797, df = 4, p = 0.434. Breen et al (2007), looked at 312 TB patients, 156 of 
whom were co-infected with HIV, and came to the conclusion that interruption of TB 
treatment occurred with similar frequency in HIV co-infected patients and those not co-
infected with HIV. This was despite a higher rate of side effects in those who were HIV 
co-infected.  
 
5.2.2  Support  
Only 28 patients (27%) took their medication without interrupting treatment. Those who 
interrupted revealed that they were mostly influenced by friends to stop treatment (37%) 
and quite surprisingly 17% were influenced by health workers to stop treatment. 
Relatives were most influential in getting patients to continue their TB treatment after 
interruption, through financial and practical help.  
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A very low number of TB patients (23%) were visited by health workers in this particular 
study. Visitation by a health worker was, however, not a significant factor associated 
with continuation of treatment in this study. χ
2
 = 3.797, df = 4, p = 0.434. In contrast 
to these findings, a randomised controlled study of 408 smear positive TB patients 
in Baghdad, Iraq, showed a significant reduction in treatment interruption by the 
participants who were visited by trained health personnel. The intervention group had a 
default rate of only 0.8% compared with 10.0% in the control group (Mohan, Nassir & 
Niazi 2003:702–8).  
 
Radio was undoubtedly the most helpful of the media in this study, and the majority of 
TB patients (81%) were exposed to TB messages during their treatment.  
 
There was a significant association between exposure to media and treatment 
interruption in this particular study. χ
2
 = 12.11, df = 4, p = 0.017.  
 
A case control study in New York found that lack of awareness and homelessness were 
significantly associated with treatment interruption. However, after further multivariate 
analysis, only lack of awareness of the severity of the disease was found to be 
significantly associated. The study emphasised the importance of increasing patient 
understanding of TB at the beginning and throughout TB treatment (Driver, Matus, 
Bayuga, Winters & Munsiff 2005:361–8). That study, however, had multiple types of 
interruptions as cases and recorded a 6% interruption rate overall.  
 
5.2.3  Reasons for and perceived consequences of stopping TB treatment 
Of the 74 respondents in this study who interrupted treatment, only 34 gave reasons 
why they interrupted. The majority cited mobility and migration issues as being their 
most important reason for interrupting, followed by lack of knowledge, side effects and 
work-related issues, yet it is interesting to note that those who moved stayed within the 
catchment area of the TB clinics. Lack of physical access, lack of family support, 
co-morbidity and other reasons constituted the remainder. Most of the respondents 




5.2.4  DOTS 
TB treatment medication was taken from a variety of locations in the district. Most 
patients (64%) preferred to take medication from home. The preference of where to take 
treatment was not a significant factor in this study. χ
2
 = 8.683, df = 8, p = 0.370.  
 
Most of the supervision in the district was not done by trained independent observers. 
Most participants indicated that they had no problem with being supervised while taking 
treatment. Observation of treatment by a second person was found not to be 
significantly associated with treatment interruption. χ
2
 = 3.911, df = 4, p = 0.418.  
 
5.2.5  Medication and side effects 
TB patients in the study experienced a variety of side effects of medication, especially 
nausea and vomiting. However, the side effects experienced were not significantly 
associated with treatment interruption in the study. χ
2
 = 4.943, df = 5, p = 0.423.  
 
In a large study on side effects in India (Dhingra et al 2004:251–9), 8.37% of 1125 TB 
patients presented with side effects, and only 0.25% of these interrupted treatment for 
short periods while on DOT. By contrast, however, a study in Hong Kong (Chang et al 
2004) finds a strong association between treatment side effects and treatment 
defaulting. In this study, 4 (1.3%) out of 306 controls experienced side effects compared 
to 10 (9.8%) out of 102 defaulters.  
 
5.2.6  Access to TB treatment 
Patients experienced a wide variety of problems in trying to access TB medication on a 
monthly basis. The mean monthly cost to get to the health centre was N$16.83. Most 
respondents did not consider the cost of travel to the centre to be expensive. It is 
important to note, however, that (81%) of respondents were living within walking 
distance of the TB clinic, so did not have to pay for transport.  
 
The cost to travel to the health centre was not a significant factor associated with 
treatment interruption in this study. χ
2
 = 7.097, df = 4, p = 0.131.  
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A survey done in Rio de Janeiro State, Brazil, found that patients who defaulted therapy 
were more likely to choose health support incentives than other patients. These 
incentives included transport and food aid. Of note, however, is that this study was done 
among the poorest in a marginalised community in the Duque de Caxias county of Rio 
de Janeiro. The study noted that among the poorest TB patients, financial support may 
be necessary to reduce treatment interruption (Belo et al 2006).  
 
The means of transport used was also not a significant factor in the study. χ
2
 = 4.527, 
df = 6, p = 0.606. In contrast, a cohort study in Southern Ethiopia reports that the need 
to use public transport is an important factor related to treatment interruption. In this 
study of 404 TB patients, 20% (81) defaulted treatment due to transport difficulties 
(Shargie & Lindtjorn 2007:e37).  
 
Distance was also not a significant factor (χ
2
 = 0.166, df = 2, p = 0.920). Most of the 
respondents (93%) lived within 5 km of the health centre.  
 
Most respondents (79.8%) in the study did not change their place of residence. Change 
of residence was not a significant factor associated with treatment interruption in this 
study (χ
2
 = 0.488, df = 2, p = 0.783), although it was mentioned by some as the reason 
for their interruption of treatment (see 5.2.3).  
 
However, contrary to the findings in this study, mobility of TB patients was found to be a 
factor influencing treatment interruption and diagnosis in injection drug users in a 
prospective cohort study in Tijuana, Mexico. Mobility was responsible for 50% of the 
treatment interruption, which occurred in 8% of that study population (Deiss et al 
2009:1491–5). An observational cohort study done in four provinces of Thailand finds 
that age, lack of DOT and mobility are significantly associated with treatment 
interruption (Kapella et al 2009:232–7).  
 
5.2.7  Patient–provider relationship 
Respondents mentioned various problems with regard to clinic attendance. Most 
(76.8%) preferred that the clinic open before 8 am. The clinic opening times in the 
research setting were 8 am to 5 pm. Monday to Friday were the preferred opening days 
for 80% of the respondents. Most (94%) of the respondents experienced a friendly 
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reception at the TB clinic and perceived the attitude at the clinics to be positive and 
caring during the time of the study.  
 
5.2.8  Stigma 
Most of the respondents in the study informed their relatives and friends about their 
diagnosis. Similarly, most respondents (83%) informed their employer; the few who did 
not disclose feared a negative response.  
 
Informing the employer was not significantly associated with treatment interruption. 
χ
2
 = 0.385, df = 2, p = 0.825.  
 
5.2.9  Substance use 
About 25% of the respondents reported that they had smoked during the week before 
the interview. However, smoking was not significantly associated with treatment 
interruption (χ
2
 = 2.476, df = 2, p = 0.290).  
 
In contrast, a study in Sri Lanka found that regular smokers were more likely to default 
compared to patients who did not smoke regularly (Pinidiyapathirage, Senaratne & 
Wickremasinghe 2008:1076–82). Another study in a rural area in Northwest Turkey 
found that the adherence rate in non-smokers was higher than in smokers, (81.4% 
and 52.4% respectively), (Balbay, Annakkaya, Arbak, Bilgin & Erbas 2005:152–8). A 
study in Hong Kong found current smoking to be a risk factor for treatment interruption 
(Chang et al 2004).  
 
Those who consumed alcohol constituted 32% of respondents. Alcohol consumption 
was not significantly associated with treatment interruption (χ
2
 = 1.128, df = 2, 
p = 0.569).  
 
In contrast, a study in South India of 676 patients showed that male alcohol consumers 
were at particularly high risk of treatment interruption (Santha, Garg, Frieden, 
Chandrasekaran, Subramani, Gopi, Selvakumar, Ganapathy, Charles, Rajamma & 
Narayanan 2002:780–8).  
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Substance use is also noted as strongly associated with non-adherence in Tomsk, 
Russia, in a retrospective study (Gelmanova, Keshavjee, Golubchikova, Berezina, 
Strelis, Yanova, Atwood & Murray 2007:703–11).  
 
5.3  RECOMMENDATIONS 
5.3.1  Recommendations for TB programme improvement 
5.3.1.1  Support for TB patients 
The problem of TB should be addressed in a holistic way. Greater focus should be 
given to poor and vulnerable populations like the study population in the Swakopmund 
district, as they are disproportionately affected by TB, both as patients and as TB 
contacts. Poverty and job creation should be addressed.  
 
Relatives should be used as treatment supporters in preference to non-relatives if at all 
possible. The community participation in TB care and prevention must be fostered at all 
times. Community health workers should work as adherence supporters in the district 
and receive appropriate incentives. These community health workers must be offered 
screening for HIV and TB, as they may be at a higher risk of HIV and TB than the 
general population (Kranzer, Bekker, Van Schaik, Thebus, Dawson, Caldwell, Hausler, 
Grant & Wood 2010:224–6).  
 
Health workers should be trained to be a positive influence to TB patients at all times. 
The alarming finding that health workers influenced treatment interruption in 
Swakopmund district should alert programmes to the existence of such a phenomenon. 
Measures should therefore be taken during training to deal effectively with 
misconceptions health workers may have regarding TB treatment. Improvement of staff 
morale must be a priority of district management.  
 
5.3.1.2  Improve patients’ understanding of TB 
The radio remains a good accessible medium of communication for TB patients and 
should be exploited to its fullest potential in all health promotion strategies. Appropriate 
health promotion messages on TB treatment should be addressed to all age groups. 
Other media types such as the cell phone should be exploited, as many people have 
access to this technology.  
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The formal education system should be harnessed as a vehicle to deliver TB messages 
within the overall country goal of universal access to education. Since health workers 
did not stand out as the primary source of information of TB in this study, an initiative 
could be launched in order to empower them to educate TB patients.  
 
5.3.3.3  Implementation of the Stop TB strategy at district level 
In line with the NTP, the district must adopt and strictly implement the DOTS/Stop TB 
strategy. This is a strategy whose vision is “a TB-free world”. One of the components is 
the pursuit of high-quality DOTS expansion and enhancement. This needs political 
support with adequate financing to pursue the goal of early case detection and 
diagnosis, and the provision of standardised treatment with proper supervision and 
support throughout. It is also important to ensure the effective supply and management 
of drugs and to put in place quality monitoring and evaluation systems to assess 
performance and impact (WHO 2011:35).  
 
Similar efforts to minimise treatment interruption should be directed to both HIV positive 
and HIV negative TB patients. Employers of TB patients are a potential resource to be 
engaged in supporting TB patients on treatment. In this study, most patients informed 
their employers of their TB status, with only a minority fearing a negative response.  
 
In terms of diagnosis, all new cases of TB considered to be at risk for MDR TB should 
be tested for drug susceptibility. This group is estimated to be 20% of all new cases and 
100% of re-treatment cases. Current data indicates that only 2% of new cases and 6% 
of re-treatment cases were tested for MDR TB globally. Strengthening laboratory 
capacity and introducing rapid diagnostic tests will assist in reaching these targets 
(WHO 2011:35).  
 
5.3.1.4  Improved access 
The Stop TB strategy objective of universal access to high quality care for all people 
with TB must be pursued in the district. Factors reducing access at the local district level 
must be eliminated (WHO 2011:35). In this study context, these will be factors such as 
clinic opening times and days, cost of travel and walking distances.  
 
72 
5.3.1.5  Research and new technology 
The NTP and the district should embrace new technology in the fight for TB. 
Operational research should continue to be conducted and results used to improve TB 
control. The district must participate in research directed at new TB drugs, vaccines and 
diagnostics. Shorter-duration TB regimens are currently being tested, and these are 
likely to increase adherence, reduce default, attract more TB patients, increase cure 
rates and reduce new cases of MDR TB (Wells et al 2010:1539).  
 
There are currently 10 new or repurposed TB drugs that are undergoing clinical trials 
and have the potential to reduce the duration of treatment of drug susceptible TB. 
Results from three phase III trials of 4-month regimens containing gatifloxacin or 
moxifloxacin for drug susceptible TB are expected by 2013. Patients must be given 
sufficient information should such a regimen change occur in the future (WHO 2011:71–
3; Wells et al 2010:1544).  
 
Xpert MTB/RIF is a fully automated, cartridge-based nucleic acid amplification test that 
can diagnose TB and drug resistant TB. This test can be used at district and subdistrict 
level. It is important to note, however, that the use of technologies such as Xpert 
MTB/RIF should be accompanied by rapid expansion of, and access to, treatment 
services. Hence the technology should be rolled out in phases, taking into account 
national plans for care and treatment of TB (WHO 2011:55).  
 
5.3.1.6  Treatment interruption definition  
The majority of patients in this study interrupted their treatment for seven days or more. 
The WHO defines treatment interruption as not taking medication for a period of one 
month but less than two months (Namibia 2006a). The existence of such a definition 
being used by TB programmes is important, but opens the door for tolerance of shorter 
periods of treatment interruption by patients, which cumulatively may pose a problem for 
both patient and community.  
 
A retrospective study based on records in Taipei found that visiting other health facilities 
during treatment was associated with TB treatment interruption of at least two months 
(Chiang, Lee, Yu, Enarson, Lin & Luh 2009:105-11). In fact, mobility of this kind was the 
only significant factor found in the study to be associated with treatment interruption. It 
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is important to note, however, that the interruptions as defined in that study differed from 
the “seven days cumulative” interruptions used in the present study, which focuses on 
shorter periods of interruption. 
 
TB programmes should not tolerate any treatment interruption. As the current WHO 
recommendation is that ART should be given to all TB patients living with HIV, 
irrespective of their CD4 count, provision of ART to TB patients should become the 
responsibility of the national TB control programme. The same level of adherence 
expected in HIV treatment should also apply to TB treatment (WHO 2011:63).  
 
Brief periods of treatment interruption can predict defaulting from TB treatment and 
should not be acceptable in TB programmes. See section 1.6.  
 
5.3.1.7  Patient preferences 
This researcher observed that in rolling out TB programmes, the economic, human 
resources and other logistic aspects often dictated the structure of the district 
programme. Patient preferences should also be considered here.  
 
A pilot study was done in Durban, South Africa, to test the feasibility of combining a 
once-daily triple combination of ARVs with a fixed-dose four-drug TB treatment regimen, 
with all drugs being given at the TB clinic as directly observed treatment first thing in the 
morning. Experiences from a cohort of 17 patients suggested that the context of directly 
observed therapy had the added benefit of creating a safer space for starting anti-
retroviral therapy in patients who would benefit the most but were not prepared to 
disclose their HIV status to others (Gebrekristos, Lurie, Mthethwa & Karim 2009:1–6).  
 
5.3.1.8  Improving the performance of the district health system  
A focus on overall strengthening of the whole district health system will benefit TB 
control. This can be done through providing more human resources for TB control, 
strengthening infection control, and upgrading laboratory capacity and efforts directed at 
the underlying determinants of health in the district.  
 
The WHO performance model outlines the functions and objectives which are important 
in turning around a poorly functioning health system. The functions include stewardship, 
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creating resources through investment and training, financing through collecting, pooling 
and purchasing and service delivery. The objectives are responsiveness, fairness in 
financial contribution and improved health (Engelbrecht & Crisp 2010:195–203).  
 
In the study context, good stewardship should ensure unity among private, public and 
non-governmental organisations in the fight against TB treatment interruption, with a 
joint strategy and common vision. Fragmentation and competition should be avoided in 
TB control. All stakeholders should be involved through public–private partnership 
approaches.  
 
In order to be ensure responsiveness, TB clinics must open as early as 7 am. Waiting 
time must be reduced. The district manager must be given authority to tailor service 
delivery in response to the local circumstances in Swakopmund district. The positive 
and caring attitude demonstrated by health care workers in this study should be 
maintained and improved on. Service delivery should take into account the cultural 
context of the individual and community.  
 
Patient representatives in decision-making bodies should be made integral to any 
planning and decision-making process in the district regarding TB care (Wells et al 
2010:1538–47).  
 
There will be a need to increase the number of TB nurses and community TB DOT 
promoters gradually, depending on available resources.  
 
The promotion of good reporting is essential for monitoring and evaluation of TB control. 
Performance targets are needed for all levels of staff.  
 
The prevention and management of multi-drug resistant TB must be scaled up in the 
district (WHO 2011:4)  
 
TB and HIV services should be integrated in the district. HIV drives the TB epidemic, 
and TB drives HIV disease progression and mortality. Integration can be achieved by 
creating a coordinating body at district level for collaborative TB and HIV activities, 
intensifying efforts at TB case finding in HIV patients and promoting HIV testing and 
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counselling, cotrimoxazole prophylaxis and early introduction of ART in TB patients 
(Matjila, Hoosen, Stoltz & Cameron 2008:89–95).  
 
5.3.2  Recommendations for further research 
The following further research is recommended: 
 
 A similar study can be done in other districts of Namibia to give a national 
perspective of the phenomenon of treatment interruption. 
 A study on the nature and quality of information obtained from health workers 
would be helpful in view of the disturbing finding that some respondents claim to 
have been influenced by health workers to stop TB treatment.  
 The questionnaire can be refined and the study repeated in the same context to 
ascertain if any change has taken place.  
 A study could be done to explore the role of the media in TB education and the 
level of understanding of such media messages by patients.  
 A further study looking further into the actual timing and number of days of TB 
treatment interruption by patients would assist the TB programme in focusing 
resources appropriately.  
 A case control design comparing the characteristics of TB treatment interrupters 
and non-interrupters is also suggested.  
 A study on patient preferences for a TB programme could be done.  
 Finally, there could be a qualitative study to explore the reasons for TB treatment 
interruption in the study context.  
 
5.4  LIMITATIONS OF THE STUDY 
5.4.1  Context 
The study was conducted under the programmatic conditions of the NTP. The NTP has 
since introduced other interventions, such as the communication for behavioural change 
(COMBI), which may change the behaviour of patients.  
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5.4.2  Study design 
The use of a questionnaire for the survey meant that some unique characteristics of 
each respondent were missed. It is also difficult to say with confidence whether the 
answers given by the TB patients reflected their true views (see 5.4.5).  
 
The survey is a descriptive cross-sectional study. If the research had measured 
confounding variables in a case control design, the effects of the confounding could 
have been found. The confounders, such as age, are related to both exposure and 
outcome.  
 
5.4.3  Sampling 
The purposive non-probability sampling method in the study means that the sample 
may not be representative, although every effort was made to include all patients 
meeting the inclusion criteria in all TB clinics during the study period.  
 
The lack of representativeness of the sample reduces the ability to generalise the 
results. No binary logistic regression was done to assess either confounding or the 
independent effect of each factor on treatment interruption.  
 
5.4.4  Data-collecting instrument 
There was a diversity of language and culture in the Swakopmund district which made it 
difficult match interviewers with respondents with respect to age, gender and language. 
It became clear during the study that the data-collecting instrument would need further 
refinement. Some of the questions were not interpreted correctly by the respondents 
and field workers.  
 
5.4.5  Ethics 
The study asked respondents to reveal deviant behaviour and personal issues. It is 
possible that some respondents would have held back their answers due to 
psychological discomfort.  
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5.5  REFLECTION ON THE STUDY 
This study on TB treatment interruption revealed to the researcher that patients 
experience a variety of positive and negative influences within their own individual 
context and environment, which determine their health behaviour. It further showed that 
a TB programme and indeed a health system must take full responsibility for the health 
of the population and not leave it to the individuals affected. Lastly, the researcher 
perceived that patients should always be involved in decisions relating to the way their 
programme was structured and run. 
 
5.6  CONCLUSION 
Treatment interruption in TB patients is a phenomenon that exists and that undermines 
the performance of the district TB programme. The study examined a number of factors 
to assist in clarifying the determinants of this major problem. DOTS remains the basic 





Abioye, IA, Omotayo, MO & Alakija, W. 2011. Socio-demographic determinants of 
stigma among patients with pulmonary tuberculosis in Lagos, Nigeria. African Health 
Sciences 11 Suppl 1:S100–04.  
Ai, X, Men, K, Guo, L, Zhang, T, Zhao, Y, Sun, X, Zhang, H, He, G, Van der Werf, MJ & 
Van den Hof, S. 2010. Factors associated with low cure rate of Tuberculosis on remote 
poor areas of Shaanxi Province, China: a case control study. BMC Public Health 
10:112. 
Babbie, E & Mouton, J. 2004. The practice of social research. Cape Town: Oxford 
University Press.  
Bailey, L, Vardulaki, K, Langham, J & Chandramohan. D. 2005. Introduction to 
Epidemiology. Berkshire: Open University Press.  
Balbay O, Annakkaya, AN, Arbak P, Bilgin C & Erbas M. 2005. Which patients are able 
to adhere to tuberculosis treatment? A study in a rural area in the northwest part of 
Turkey. Japanese Journal of Infectious Diseases 58(3):152–8.  
Bangalore, S, Kamalakkannan, G, Parkar, S & Messerli, FH. 2007. Fixed-dose 
combinations improve medication compliance: A meta-analysis. The American Journal 
of Medicine 120(8):713–19.  
Belo, MT, Selig, L, Luiz, RR, Hansen, C, Luna, AL, Teixeira, EG & Trajman, A. 2006. 
Choosing incentives to stimulate tuberculosis treatment compliance in a poor county in 
Rio de Janeiro state, Brazil. Medical Science Monitor: International Journal 12(5):PH1–5.  
Breen, RA, Miller RF, Gorsuch T, Smith CJ, Schwenk, A, Holmes, W, Ballinger, J, 
Swaden, L, Johnson, MA, Cropley, I & Lipman, MC. 2006. Adverse events and treat-
ment interruption in tuberculosis with or without HIV co-infection. Thorax 61(9):791–4.  
Brink, H, Van der Walt, C & Van Rensburg, G. 2006. Fundamentals of research 
methodology for health care professionals. Cape Town: Juta. 
79 
CDC. See Centers for Disease Control and Prevention. 
Centers for Disease Control and Prevention. 2006. Notice to readers: Revised definition 
of extensively drug-resistant tuberculosis. JAMA 296(23):2792 From: www.jama.ama-
assn.org/content/296/23/2792.1.full.pdf (accessed 19 May 2011).  
Chang, KC, Leung, CC & Tam, CM. 2004. Risk factors for defaulting from anti-
tuberculosis treatment under DOT in Hong Kong. International Journal of Tuberculosis 
and Lung Disease 8(12):1492–8.  
Chiang, CY, Lee, JJ, Yu, MC, Enarson, DA, Lin, TP & Luh, KT. 2009. Tuberculosis 
outcomes in Taipei: Factors associated with treatment interruption for 2 months and 
death. International Journal of Tuberculosis and Lung Disease 13(1):105–11.  
Date, J & Okita, K. 2005. Gender and literacy: Factors related to diagnostic delay and 
unsuccessful treatment of tuberculosis in the mountainous area of Yemen. The 
International Journal of Tuberculosis and Lung Disease 9(6):680–5. 
Datiko, DG, Lindtjørn, B. 2009. Health extension workers improve tuberculosis case 
detection and treatment success in Southern Ethiopia: A community randomized trial. 
PLoS ONE 4(5):e5443.  
Deiss, R, Garfein, RS, Lozada, R, Burgos, JL, Brouwer, KC, Moser, KS, Zuniga, ML, 
Rodwell, TC, Ojeda, VD & Strathdee, SA. 2009. Influences of cross-border mobility on 
tuberculosis diagnoses and treatment interruption among injection drug users in 
Tijuana, Mexico. American Journal of Public Health 99(8):1491–5.  
Dhingra, VK, Rajpal, S, Aggarwal, N, Aggarwaln, JK, Shadab, K & Jain, SK. 2004. 
Adverse drug reactions observed during DOTS. The Journal of Communicable 
Diseases 36(4):251–9.  
Dodor, EA & Afenyadu, GY. 2005. Factors associated with tuberculosis treatment 
default and completion at the Effia-Nkwanta Regional Hospital in Ghana. Transactions of 
the Royal Society of Tropical Medicine and Hygiene 99(11):827–32.  
80 
Driver, CR, Matus, SP, Bayuga, S, Winters Al & Munsiff SS. 2005. Factors associated 
with tuberculosis treatment interruption in New York City. Journal of Public Health 
Management and Practice 11(4):361–8.  
Eastwood, SV & Hill, PC. 2004. A gender focused qualitative study of barriers to 
accessing tuberculosis treatment in The Gambia, West Africa. International Journal of 
Tuberculosis and Lung Disease 8(1):70–75.  
Engelbrecht, B & Crisp, N. 2010. Improving the performance of the health system, 
Chapter 19 in South African Health Review 2010, editors A Padarath & S Fonn. Durban: 
Health Systems Trust: 195–203. From: www.hst.org.za/sites/default/files/sahr10_19.pdf 
(accessed 24 October 2011).  
Faustini, A, Hall, AJ & Perucci, CA. 2006. Risk factors for MDR in Europe: Systematic 
review. Thorax 61(2):158–63.  
Frieden, TR & Sbarbaro, JA. 2007. Promoting adherence to treatment for tuberculosis: 
The importance of direct observation. World Hospitals and Health Services 43(2):30–33.  
Gebrekristos, HT, Lurie, MN, Mthethwa, N & Karim, QA. 2009. Disclosure of HIV status: 
Experiences of patients enrolled in an integrated TB and HAART pilot programme in 
South Africa. African Journal of AIDS Research 8(1):1–6.  
Gelmanova, IY, Keshavjee, S, Golubchikova, VT, Berezina, VI, Strelis, AK, Yanova, GV, 
Atwood, S & Murray, M. 2007. Barriers to successful tuberculosis treatment in Tomsk, 
Russian Federation: Non-adherence, default and acquisition of multidrug resistance. 
Bulletin of the World Health Organisation 85(9):703–11.  
Gopi PG, Vasantha, M, Muniyandi, M, Chandrassekaran, V, Balasubramanian, R & 
Narayanan, R. 2007. Risk factors for non-adherence to directly observed treatment 
(DOT) in a rural tuberculosis unit, South India. The Indian Journal of Tuberculosis 
54(2):66–70.  
81 
Gupta, S, Gupta, S & Behera. 2011. Reasons for interruption of anti-tubercular 
treatment as reported by patients with tuberculosis admitted in a tertiary care institute. 
The Indian Journal of Tuberculosis 58(1):11–17. 
Jaiswal, A, Singh, V, Ogden, JA, Porter, JD, Sharma, PP, Sarin, R, Arora, VK & Jain, 
RC. 2003. Adherence to tuberculosis treatment: Lessons from the urban setting of 
Delhi, India. Tropical Medicine and International Health 8(7):625–33.  
Jakubowiak, W, Bogorodskaya, E, Borisov, S, Danilova, I & Kourbatova, E. 2009. 
Treatment interruptions and durations associated with default among new patients with 
tuberculosis in six regions of Russia. International Journal of Infectious Diseases 
13(3):362–8.  
Jakubowiak, WM, Bogorodskaya, E, Borisov, S, Danilova, I & Kourbatova, E. 2007. Risk 
factors associated with default among new pulmonary TB patients and social support in 
six Russian regions. International Journal of Tuberculosis and Lung Disease 11(1):46–53.  
Jaramillo, E. 1999. Tuberculosis and stigma: Predictors of prejudice against people with 
tuberculosis. Journal of Health Psychology 4:71. 
Jittimannee, SX, Kateruttanakul, P, Madigan, EA, Jittimannee, S, Phatkrathok S, 
Poomichaiya, P & Panitrat, R. 2006. Medical characteristics and tuberculosis treatment 
outcomes in an urban tertiary hospital, Thailand. The South East Asian Journal of 
Tropical Medicine and Public Health 37(2):338–44.  
Kaona FA, Tuba M, Siziya S & Sikaona L. 2004. An assessment of factors contributing 
to treatment adherence and knowledge of TB transmission among patients on TB 
treatment. BMC Public Health 4:68. 
Kapella, BK, Anuwatnonthakate, A, Komsakorn, S, Moolphate, S, Charusontonsri, P, 
Limsomboon, P, Wattanaamornkiat, W, Nateniyom, S & Varma, JK. 2009. Directly 
observed treatment is associated with reduced default among foreign tuberculosis 
patients in Thailand. International Journal of Tuberculosis and Lung Disease 13(2):232–7. 
82 
Khan, MA, Walley, JD, Witter, SN, Shah, SK & Javeed, S. 2005. Tuberculosis patient 
adherence to direct observation: Results of a social study in Pakistan. Health Policy and 
Planning 20(6):354–65.  
Kranzer, K, Bekker, LG, van Schaik, N, Thebus, L, Dawson, M, Caldwell, J, Hausler, H, 
Grant, R & Wood, R. 2010. Community health workers in South Africa are at increased 
risk for tuberculosis. South African Medical Journal 100(4):224–6.  
Lagrada, LP, Uehara, N & Kawahara, K. 2008. Analysis of factors of treatment 
completion in DOTS health facilities in metro Manila, Philippines: A case control study. 
Kekkaka [Tuberculosis] 83(12):765–72.  
Lewin, S, Dick, J, Zwarenstein, M & Lombard, CJ. 2005. Staff training and ambulatory 
treatment outcomes. A cluster randomized controlled trial in South Africa. Bulletin of the 
World Health Organisation 83(4):250–9.  
Maltby, M, Day, L & Williams, G. 2007. Introduction to Statistics for Nurses. Essex: 
Pearson Education Limited.  
Mateus-Solarte, JC & Carvajal-Barona, R. 2008 . Factors predictive of adherence to 
tuberculosis treatment, Valle del Cauca, Colombia. International Journal of Tuberculosis 
and Lung Disease, May 12(5):520–26.  
Matjila, MJ, Hoosen, AA, Stoltz, A & Cameron, N. 2008. STIs, HIV and AIDS and TB: 
Progress and challenges. Chapter 6 in South African Health Review 2008, editors 
P Barron & J Roma-Reardon. Durban: Health Systems Trust: 89–102. From: 
www.hst.org.za (accessed 25 October 2011).  
Mishra, P, Hansen, EH, Sabroe, S, Kafle, KK. 2005. Socioeconomic status and 
adherence to tuberculosis treatment: A case control study in a district in Nepal. 
International Journal of Tuberculosis and Lung Disease 9(10):1134–9.  
Mishra, P, Hansen, EH, Sabroe, S & Kafle, KK. 2006. Adherence is associated with the 
quality of professional–patient interaction in DOTS. Patient Education and Counselling 
63(1–2):29–37.  
83 
Mohan, A, Nassir, H & Niazi, A. 2003. Does routine home visiting improve the return 
rate and outcome of DOTS patients who delay treatment? Eastern Mediterranean 
Health Journal 9(4):702–8.  
Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A & Volmink, J. 2007a. Patient 
adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS 
Medicine 4(7):e238.  
Munro, SA, Lewin, S, Swart, T & Volmink, J. 2007b. A review of health behaviour 
theories: How useful are these for developing interventions to promote long term 
medication adherence for TB and HIV/AIDS? BMC Public Health Research, 11 June 
7(147):104. From: www.ncbi.nlm.nih.gov/pmc/articles/PMC1925084/?tool=pubmed 
(accessed 17 February 2012). 
Naidoo, P, Dick, J & Cooper, D. 2009. Exploring tuberculosis patients’ adherence to 
treatment regimens and prevention programs at a public health site. Qualitative Health 
Research 19(1):55–70.  
Namibia. 2003. 2001 Population and housing census: Erongo Region: Basic analysis 
with highlights. Windhoek: National Planning Commission.  
Namibia. 2006a. National guidelines for the management of tuberculosis. Windhoek: 
Ministry of Health and Social Services. 
Namibia. 2007. Swakopmund District Annual Report 2006/7. Swakopmund: Ministry of 
Health and Social Services.  
Namibia. 2008a. 2006–07 Namibia demographic and health survey. Windhoek: Ministry 
of Health and Social Services. From: www.measuredhs.com/pubs/pdf/PB4/PB4.pdf 
(accessed 17 February 2012). 
Namibia. 2008b. National Tuberculosis and Leprosy Control Programme Annual Report 
2007/2008. Windhoek: Ministry of Health and Social Services.  
84 
Namibia. 2008c. Report of the 2008 National HIV Sentinel Survey. Windhoek: Ministry 
of Health and Social Services.  
Namibia. 2008d. Swakopmund District Annual Report 2007/8. Swakopmund: Ministry of 
Health and Social Services.  
Namibia. 2009a. National Tuberculosis and Leprosy Control Programme Annual Report 
2008/2009. Windhoek: Ministry of Health and Social Services.  
Namibia. 2009c. Official Address by the Minister of Health on World TB Day. Windhoek: 
Ministry of Health and Social Services.  
Noyes, J & Popay, J. 2007. Directly observed therapy and tuberculosis: How can a 
systematic review of qualitative research contribute to improving services? A qualitative 
meta-synthesis. Journal of Advanced Nursing 57(3):227–43.  
Nutbeam, D & Harris, E. 2004. Theory in a Nutshell. A practical guide to health 
promotion theories. New South Wales: McGraw-Hill.  
Okeibunor, JC, Onyeneho, NG, Chukwu, JN & Post, E. 2006. Barriers to care seeking in 
directly observed therapy short-course (DOTS) clinics and tuberculosis control in 
Southern Nigeria: A qualitative analysis. International Quarterly of Community Health 
Education 27(1):23–27 
Peltzer, A. 2002. Factors at first diagnosis of tuberculosis associated with compliance 
with directly observed therapy (DOT) in the Limpopo province, South Africa. Curationis 
25(3):55–67.  
Pinidiyapathirage, J, Senaratne, W & Wickremasinghe, R. 2008. Prevalence and 
predictors of default with tuberculosis treatment in Sri Lanka. South East Asian Journal 
of Tropical Medicine and Public Health 39(6):1076–82.  
Rintiswati, N, Mahendradhata, Y, Suhama, Susulawati, Purwanta, Subronto, Y, 
Varkevisser, CM & van der Werf, MJ. 2009. Journeys to tuberculosis treatment: A 
85 
qualitative study of patients, families and communities in Jogjakarta, Indonesia. BMC 
Public Health 27(9):158.  
Sagbakken, M, Frich, JC & Bjune, G. 2008. Barriers and enablers in the management of 
tuberculosis treatment in Addis Ababa, Ethiopia: A qualitative study. BMC Public Health 
8:11.  
Saks, M & Allsop, J. 2008. Researching health: Qualitative, quantitative and mixed 
methods. London: SAGE.  
Santha, T, Garg, R, Frieden, TR, Chandrasekaran, V, Subramani, R, Gopi, PG, 
Selvakumar, N, Ganapathy, S, Charles, N, Rajamma, J & Narayanan, PR. 2002. Risk 
factors associated with default, failure and death among tuberculosis patients treated in 
a DOTS programme in Tiruvallur District, South India, 2000. International Journal of 
Tuberculosis and Lung Disease 6 (9):780–8.  
Shargie, E & Lindjorn, B. 2007. Determinants of treatment adherence among smear 
positive tuberculosis patients in Southern Ethiopia. PLoS Medicine 4(2):e37. 
Sharma, N, Nath, A, Taneja, DK & Ingle GK. 2009. A qualitative evaluation of 
information, education and communication component of the tuberculosis control 
program in Delhi, India. Asia-Pacific Journal of Public Health 21(3):321–32.  
Sinanovic, E & Kumaranayake, L. 2006. Quality tuberculosis care provided in different 
models of public–private partnerships in South Africa. International Journal of 
Tuberculosis and Lung Disease 10(7):795–801.  
Somma, D, Thomas, BE, Karim, F, Kemp, J, Arias, N, Auer, C, Gosoniu, GD, Abouihia, 
A & Weiss, MG. 2008. Gender and socio-cultural determinants of TB-related stigma in 
Bangladesh, India, Malawi and Colombia. International Journal of Tuberculosis and 
Lung Disease 12(7):856–66.  
South Africa. 1919. Public Health Act 36 of 1919, as amended by SA Proclamation 36 
of 1920. Pretoria: Government Printer.  
86 
Suri, A, Gan, K & Carpenter, S. 2007. Voices from the field: Perspectives from 
community health workers on health delivery in rural KwaZulu-Natal, South Africa. The 
Journal of Infectious Diseases 196. Suppl. 3:S505–11.  
Tanrikulu, AC, Hosoglu, S, Ozekinci, T, Abakay, A & Gurkan, F. 2008. Risk factors for 
drug resistant tuberculosis in southeast Turkey. Tropical Doctor 38(2):91–3.  
Tupasi, TE, Radhakrishna, S, Chua, JA, Mangubat, NV, Guilatco, R, Galipot, M, 
Ramos, G, Quelapio, MID, Beltran, G, Legaspi, J, Vianzon, RG & Lagahid, J. 2009. 
Significant decline in the tuberculosis burden in the Philippines ten years after initiating 
DOTS. International Journal of Tuberculosis and Lung Disease; 13(10):1224–1230.  
USAID. 2011. DOTS Expansion and Enhancement. From: www.usaid.gov/our_work/ 
global_health/id/tuberculosis/techareas/dots.html (accessed 17 February 2012).  
Van Dulmen, S, Sluijs, E, van Dijk, L, de Ridder, D, Heerdink, R & Bensing, J. 2007. 
Patient adherence to medical treatment: A review of reviews. BMC Health Services 
Research 7:55.  
Volmink, J & Garner, P. 2007. Directly observed therapy for treating tuberculosis. 
Cochrane Database of Systematic Reviews (4):CD003343.  
Wells, WA, Konduri, N, Chen, C, Lee, D, Ignatius, HR, Gardiner, E & Schwalbe, NR. 
2010. Tuberculosis regimen change in high burden countries. International Journal of 
Tuberculosis and Lung Disease 14(12):1538–47.  
WHO. 2003. Management of tuberculosis training for health facility staff. Geneva: WHO. 
From: whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.314g.pdf (accessed 17 
February 2012).  
WHO. 2008. Community-based care can improve access. From: 
www.who.int/tb/people_and_communities/involvement/community_who_story_sep08.pdf 
(accessed 17 February 2012).  
87 
WHO. 2011. Global tuberculosis control 2011. WHO Report. Geneva. From: www.who. 
int/tb/publications/global_report/en/ (accessed 17 February 2012). 
Williams, G, Alarcon, E, Jittimanee, S, Walusimbi, M, Sebek, M, Berga, E & Villa, TS. 
2008. Care during the intensive phase: Promotion of adherence. International Journal of 
Tuberculosis and Lung Disease 12(6):601–5.  
Zvavamwe, Z & Ehlers, VJ. 2009. Experiences of a community based tuberculosis 
treatment programme in Namibia: A comparative cohort study. International Journal of 
Nursing Studies 46(3):302–9.  
 
LIST OF SOURCES CONSULTED BUT NOT REFERRED TO 
Chang-Yeung, M, Noertjojo, K, Leung, CC, Chan, SI & Tam, CM. 2003. Prevalence and 
predictors of default from tuberculosis treatment in Hong Kong. Hong Kong Medical 
Journal 9(4):263–8.  
Corless, IB, Nicholas, PK, Wantland, D, McInerney, P, Ncama, B, Bhengu, B, 
McGibbon, CA & Davis, SM. 2006. The impact of meaning of life and life goals on 
adherence to a tuberculosis medication regimen in South Africa. International Journal of 
Tuberculosis and Lung Disease 10(10):1159–65.  
Cox, HS, Morrow, M & Deutschmann, PW. 2008. Long-term efficacy of DOTS 
regimen for tuberculosis: Systematic review. BMJ 336:484–7. From: www.bmj.com/ 
content/336/7642/484.full (accessed 18 February 2012). 
Daniel, OJ, Oladapo, OT & Alausa, OK. 2006. Default from tuberculosis treatment 
programme in Sagamu, Nigeria. Niger Journal of Medicine 15(1):63–7.  
Davidson, H, Schluger, NW, Feldman, PH, Valentine, DP, Telzak, EE & Laufer, FN. 
2000. The effects of increasing incentives on adherence to tuberculosis directly 
observed therapy. International Journal of Tuberculosis and Lung Disease 4(9):860–5.  
88 
Deiss, R, garfein, RS, Lozada, R, Burgos, JL, Brouwer, KC, Moser, KS, Zuniga, ML, 
Rodwell, TC, Ojeda,VD & Strathdee, SA. 2009. Infuences of crossborder mobility in 
tuberculosis diagnosis and treatment interruption among injection drug users in Tijuana, 
Mexico. American Journal of Public Health 99(8): 1491-5. 
Dick, J. 1999. The study of the determinants of non-adherence to anti-tuberculous 
treatment: Are we using appropriate research methodology? International Journal of 
Tuberculosis and Lung Disease 3(11):1049.  
Edelman, CL & Mandle, CL. 2010. Health promotion throughout the lifespan. Boston: 
Mosby Elsevier.  
Engelbrecht, M, Janse van Rensburg, E, Matebesi Z, Heunis, C, van Rensburg, D, 
Elgoni, A & McCoy, D. 2001. Tuberculosis in Hlanganani Health District (Free  
State): A situation analysis. Durban: Health Systems Trust. From: 
www.hst.org.za/publications/tuberculosis-hlanganani-health-district-free-state-situation-
analysis (accessed 24 October 2011).  
Hoek, KJP, Schaaf, HS, Cey van Pittius, NC, van Heiden, PD & Warren, RM. 2009. 
Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. 
South African Medical Journal 99(11):785–7.  
Hubbard, D. 2010. NAMLEX – 2010: Index to the laws of Namibia. Legal Assistance 
Centre. From: www.lac.org.na/namlex/Health.pdf (last accessed 17 February 2012).  
Janmeja, AK, Das, SK, Bhargava, R, Charan, BS & Chandigarh. 2005. Psychotherapy 
improves compliance with tuberculosis treatment. Respiration 72(4):375–80.  
Kirkwood, BR & Sterne, JAC. 2006. Essential Medical Statistics. Oxford: Blackwell.  
Kruk, ME, Schwalbe, NR & Aguiar, CA. 2008. Timing of default from tuberculosis 
treatment: A systematic review. Tropical Medicine and International Health 13(5):703–12.  
89 
Meldrum, J. 2003. Durban pilots once daily ARVs with DOTS treatment for TB. 
AIDSMAP,12 August 2003. From: http://www.aidsmap.com/Durban-pilots-once-daily-
ARVs-with-DOTS-treatment-for-TB/page/1416471 (accessed 25 October 2011).  
Morsy, AM, Zaher, HH, Hassan, MH & Shouman, A. 2003. Predictors of treatment 
failure among tuberculosis patients under DOTS strategy in Egypt. Eastern 
Mediterranean Health Journal 9(4):689–701.  
Moulding, T, Mateus-Solarte, JC & Carvajal-Barona, R. 2009. Factors predictive of 
adherence to tuberculosis treatment, Valle del Cauca, Colombia. International Journal 
of Tuberculosis and Lung Disease, Mar 13(3):416-7. 
Namibia. 2006b. Swakopmund District Annual Report 2005/6. Swakopmund: Ministry of 
Health and Social Services.  
Namibia. 2009b. National Tuberculosis Resistance Survey Report. Windhoek: Ministry 
of Health and Social Services.  
Padayatchi, N, Naidoo, K, Dawood, H, Kharsany, A & Karim, QA. 2010. A review of 
progress on HIV, AIDS and tuberculosis, Chapter 9 in South African Health Review 
2010, editors A Padarath & S Fonn. Durban: Health Systems Trust: 87–100. From: 
www.hst.org.za/publications/south-african-health-review-2010 (accessed 24 October 
2011).  
Rocha, M, Pereira, S, Ferreira, L & Barros, H. 2003. The role of adherence in 
tuberculosis HIV-positive patients treated in ambulatory regimen. The European 
Respiratory Journal 21(5):785–8.  
Salles, CL, Conde, MB, Hofer, C, Cunha, AJ, Calcada, AL, Menezes, DF, Sa, L & 
Kritski, AL. 2004. Defaulting from anti-tuberculous treatment in a teaching hospital in 
Rio de Janeiro, Brazil. International Journal of Tuberculosis and Lung Disease (3):318–
22.  
Stanhope, M & Lancaster, J. 2009. Foundations of Community Health Nursing: 
Community-oriented practice; 3rd edition. St Louis: Mosby.  
90 
Thiam, S, LeFevre, AM, Hane, F, Ndiaye, A, Ba, F, Fielding, KI, Ndir, M & Lienhardt, C. 
2007. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a 
resource-poor setting: A cluster randomized controlled trial. The Journal of the American 
Medical Association 24 297(4):380–6.  
Trochim, WMK. 2006. The Research Methods Knowledge Base; 2nd edition. Web 
Center for Social Research Methods. From: www.socialresearchmethods.net/kb/ 
(accessed 2 January 2010).  
91 
 
ANNEXURE A: RESEARCH & ETHICS COMMITTEE CLEARANCE CERTIFICATE 
  
UNIVERSITY OF SOUTH AFRICA 
Health Studies Research & Ethics Committee 
(HSREC)  




Date of meeting: 5 July 2007.  Project No: 35757299 
 
Project Title: TREATMENT INTERRUPTION IN TUBERCULOSIS PATIENTS  
IN A DISTRICT OF NAMIBIA  
 
Researcher: Dr T Zaranyika  
  
Supervisor/Promoter:  Dr A D Botha  
Joint Supervisor/Joint Promoter:  Dr S Knight  
Department:  Health Studies 
Degree:  Master of Public Health 
 
DECISION OF COMMITTEE 
 
Approved    Conditionally Approved      
  
Date: 10 Sept 2007 
 
Prof L de Villiers 
RESEARCH COORDINATOR: DEPARTMENT OF HEALTH STUDIES 
 
Prof SM Mogotlane 
ACADEMIC CHAIRPERSON: DEPARTMENT OF HEALTH STUDIES 
 


























I ,   ............................................................. ,  con f i rm tha t  I  was fu l l y  in fo rmed 
o f  the  resea rch  p ro jec t .   
I  am aware  tha t  my p r i vacy w i l l  be  sa fegua rded  and  tha t  a l l  
i n fo rmat ion  I  sha re  w i th  the  resea rche r  w i l l  be  con f iden t ia l .   
I  am aware  tha t  I  can  wi thd raw f rom pa r t i c ipa t ion  a t  any t ime  and  
tha t  t h i s  w i l l  no t  in f luence  the  hea l th  ca re  g i ven  to  me .   
I  have  been in fo rmed tha t  I  w i l l  no t  su f fe r  any  in ju ry  o r  ha rm dur ing  
the  resea rch  p rocess .   
The  in fo rmat ion  tha t  I  w i l l  g i ve  the  researche r  shou ld  no t  be  used  
aga ins t  me in  fu ture .   
 
 
Name  .....................................................................................................................................  
 
 
S igna tu re   ............................................................................................................................  
 
 
Da te  .........................................................................................................................................  
 
 
P lace  .......................................................................................................................................  
 
94 
Questionnaire – Page 1 
ANNEXURE D: QUESTIONNAIRE 
SECTION A – PATIENT CHARACTERISTICS (DEMOGRAPHIC DATA)  
  
1.  Age … … 
2.  Gender: 1. Male …   2. Female … 
3.  Present address of patient  ..................................................................................  
  ................................................................................................................................  
4.  Formal Educational Level 
 1. None …   2. Primary …   3. Secondary …  4. Tertiary …  
5.  Employment status  
 1. Employed …   2. Unemployed … 
6.  Income bracket1  
 1. Low …     2. Medium …    3. High …  
7.  Who did you stay with during your TB treatment?  ........................................... 
  ................................................................................................................................  
8.  HIV status (from TB records)  
 1.  Positive …   2. Negative …    3. Unknown … 
 
SECTION B – SUPPORT 
 
TB patients are often influenced to continue or stop treatment by another person.  
1a.  Did you complete TB treatment?  
 1. Yes …     2. No …     3. Don’t know …  
1b.  If “No”, who in the community influenced you to stop your TB treatment? 
 ..........................................................................................................................................  
 ..........................................................................................................................................  
1c.  Which of the following were most influential in your stopping of TB 
treatment?  
 1. Friend …    2. Relative …    3. Neighbour …  
 4. Health care worker …  5. Traditional healer …  6. Other …  
Specify other  ..................................................................................................................  
1d.  If yes, who in the community influenced you to continue your TB treatment? 
 ..........................................................................................................................................  
                                            
1  Note: Income categories: 
 low < N$400/month; medium N$400–1500/month; high > N1500/month 
 
 Questionnaire – Page 2 
1e.  Which of the following were most influential in you continuing your TB 
treatment after you stopped taking it? 
1. Friend …     2. Relative …    3. Neighbour …  
4. Health care worker …   5. Traditional healer …  6. Other …  
Specify other  ..................................................................................................................  
 
2a.  Were you ever visited by a health worker while on TB treatment?  
 1. Yes …   2. No …   3. Don’t know  …  
2b.  Who was the person, and how often did they visit you?  ..................................... 
  ..........................................................................................................................................  
 
3a.  People hear about TB from different people in different places. Since starting 
TB treatment where did you learn the most about TB? 
 ..........................................................................................................................................  
3b.  Which of the following was most important to help you to understand about 
TB?  
 1. Radio …  2. TV …   3. Print …   4. Cellphone message …  
5. Other (specify)  ...........................................................................................................  
3c.  Have you ever been exposed to any TB messages in the media after starting 
TB treatment?  
 1. Yes …   2. No …   3. Don’t know … 
3d.  If yes, what media? 
1. Radio …  2. TV …   3. Print …   4. Cellphone …  
5. Other (specify)  ...........................................................................................................  
 
SECTION C – REASONS FOR AND PERCEIVED CONSEQUENCES OF STOPPING  
TB MEDICINES 
 
1a.  Why did you stop taking your TB treatment?  ....................................................  
  ................................................................................................................................  
1b.  Which of the following reasons would you say are most important for you 
having stopped your TB treatment? 
1. Lack of physical access …   2. Lack of financial access …  
3. Lack of family support …   4. Side effects …  
5. Co-morbidity …     6. Lack of knowledge …  
7. Beliefs and perceptions …   8. Work related issues …  
9. Mobility and migration …  10. Programmatic factors & incentives …  
11. Other (specify)  .................................................................................................. 
 ................................................................................................................................  
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2a. Why do you think you need to continue to take TB medicines for six months? 
 ................................................................................................................................  
 ................................................................................................................................  
2b.  What do you think are the most important consequences of stopping your 
TB medicines?  
 1. Nothing …  2. Will become more sick …  3. Death …  
 4. Transmission to others …  5. Multi-drug resistant TB …   
6. Other (specify)  ...........................................................................................................  
 
SECTION D – DIRECTLY OBSERVED THERAPY 
 
1a.  Where did you take your TB treatment in the beginning?  
1b.  During the last month you are on treatment where did you take your 
treatment?   
1c.  Where would you prefer to take your TB treatment?  
 1. Community …  2. Health centre …  3. Home …  
 4. Hospital …  5. Someone else’s home …  
6. Other (specify)  ...........................................................................................................  
  
2a.  Did a second person supervise you taking your medicines each time?   
 1. Yes …   2. No …  3. Don’t know … 
2b.  Please describe who supervised you and how they supervised you taking 
your TB medicines   
  ................................................................................................................................  
  ................................................................................................................................  
2c.  Some people like being supervised to take their medicines and others don’t 
like it. How did you feel about having to be supervised to take medicines? 
  ................................................................................................................................  
  ................................................................................................................................  
 
SECTION E – MEDICATION AND SIDE EFFECTS 
 
1a.  What effect did the medicine have on you?  .......................................................  
  ................................................................................................................................  
  ................................................................................................................................  
1b.  What did you do about this problem?  ................................................................ 
  ................................................................................................................................  
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2a.  Who did you show (talk about) this problem to?  .............................................. 
  ................................................................................................................................   
2b.  What were they able to do about it?  ................................................................... 
  ................................................................................................................................ 
  ................................................................................................................................  
 
3.  What were the worst unwanted side effects from the TB medicines?  
 1. Skin problems …  2. Yellow eyes …  3. Nausea and vomiting …  
 4. Joint/limb pains …  5. Dizziness & headaches …   
 6. Other, specify  ..................................................................................................... 
  ................................................................................................................................  
 
SECTION F – ACCESS  
 
1a.  What were the biggest problem you experienced getting your TB medicines 
from the clinic on a monthly basis?  ...................................................................  
  ................................................................................................................................  
1b.  How much did it cost you to get to the health centre monthly?  ......................  
1c.  How long did it take you from the time that you left home to the time that you 
are right back with your TB treatment?  .............................................................  
 
2.  The cost of travelling to the health centre is:  
 1. Not expensive …   2. Expensive …   3. Very expensive … 
 
3.  What means of transport do you use to get to the TB clinic?  
 1. Foot …   2. Bicycle …    3. Taxi …   
 4. Donkey cart …  5. Employer’s car …   6. Other …   
 Specify other   
 
4.  Estimate the distance between your home and the health centre.  
 1. 0–5 km …   2. 6–10 km …    3. 11–15 km … 
 4. 16–20 km …   5. More than 20 km … 
 
5.  Where were you staying when you started taking your TB treatment?  ...........  
  ..........................................................................................................................................  
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6.  Where were you staying at the time you discontinued taking your treatment?
   ...............................................................................................................................  
 
7.  Did you change your place of residence during your TB treatment?  
 1. Yes …    2. No …   3. Don’t know … 
 
SECTION G – PATIENT–PROVIDER RELATIONSHIP 
 
Some patients discontinue treatment because of problems with attending the clinics.  
 
1. Did you have any problems attending the clinics? Describe the problems: … 
  ................................................................................................................................  
  ................................................................................................................................  
 
2.  What are your preferred clinic opening times? 
 1. Earlier than 8am and up to 5pm …  2. From 8 am to 5pm …  
 3. From 8 am till later than 5pm …  4. Earlier than 8 am till later than 5pm …  
5. Other (specify)  ...........................................................................................................  
 
3.  What are your preferred opening days?  
1. Mon–Fri …   2. Mon–Fri plus weekends …  3. Special days for TB … 
 
4.  How would you describe the reception you got at the health centre?  
 1. Friendly …   2. Unfriendly …    3. Indifferent …  
 
SECTION H – STIGMA 
 
1.  These days it is not always easy to tell people you have got TB. How did you 
feel about sharing that you had TB with other people?   
  ................................................................................................................................  
  ................................................................................................................................ 
  ................................................................................................................................  
 
2.  Whom are you able to tell that you are suffering from TB?  ............................. 
  ................................................................................................................................  
  ................................................................................................................................  
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3.  Did you inform your friends or relatives about your TB treatment?  
 1. Yes …     2. No …     3. Don’t know … 
 
4.  If no, why? 1. Fear of negative response … 2. Have no friends/relatives …  
3. Other (specify)  ...........................................................................................................  
 
5.  Did your friends and relatives assist you in any way with:  
 1. Food …    2. Transport …    3. Money …  
 4. Other (specify)  ....................................................................................................  
 
6.  If employed, did you tell your employer that you are on TB treatment?  
1. Yes …      2. No …  
 
7.  If NO, why?  
 1. Fear of losing job …  2. Fear of isolation at work …  
 3. Fear of losing income …  4. Other reason (specify)  .....................................  
  ................................................................................................................................  
 
SECTION I – SUBSTANCE USE 
 
1a.  Do you smoke cigarettes?  
 1. Yes …   2. No …   3. Don’t know … 
1b.  If yes, in the last week have you smoked cigarettes?  
 1. Yes …   2. No …   3. Don’t know … 
1c.  How long does a pack of 20 cigarettes last you?  ................................................. 
  
2a.  Do you consume alcohol?  
 1. Yes …   2. No …   3. Don’t know … 
2b.  In the last week, have you consumed alcohol?  
 1. Yes …   2. No …   3. Don’t know … 
2c.  In the last week, how many pints of beer have you consumed?  .......................  
 
 
THANK YOU.  
 
